Our cover: Band of osteoblasts by toluidine blue staining (40X).

Authorship: Group of Bone, Vascular Metabolism and Chronic Inflammatory Diseases. Health Research Institute of the Principality of Asturias (ISPA), Central University Hospital of Asturias, Oviedo (Spain).

Summary

Vol. 13 - Nº 4 - November-December 2021

EDITORIAL
Sequential treatment: it has come a long way... with a long way to go
González Macías J .............................................................. 105

SPECIAL ARTICLE
Sequential treatment in osteoporosis. New trends
Casado E, Neyro JL ...................................................................... 107

ORIGINALS
WNT16 rs2908004 missense variant acts as eQTL of FAM3C in human primary osteoblasts
Martínez-Gil N, Patiño J, Ugartondo N, Grinberg D, Balcells S .......... 117

Diet as a risk factor for hypovitaminosis D in the Spanish pediatric population
Blarduni Cardón E, Arrospide A, Angulo Ugarte H, Urrutia Etxebarria I, Castaño González I, Etxebarria I, Mar J, Grupo Goivide .............. 122

Genetic relationship between pulmonary diseases of environmental or occupational origin and osteoporosis: a bioinformatic approach

Muscle strength as a predictor of bone fragility in patients with type 2 diabetes mellitus
Hayón-Ponce M, García-Fontana B, Avilés-Pérez MD, González-Salvaterra S, Moratalla-Aranda E, Muñoz-Torres M .................. 137

Indexed in: Scielo, Web of Sciences, IBRCS, Scopus, SIIIC Data Bases, embase, Redalyc, Emerging Sources Citation Index, Open J-Gate, DOAJ, Free Medical Journal, Google Academic, Medes, Electronic Journals Library AZB, e-revistas, WorldCat, Latindex, EBSCOhost, MedicLatina, Dialnet, SafetyLit, Mosby’s, Encare, Academic Keys, ERljh plus, British Library, ROAD.

Revista de Osteoporosis y Metabolismo Mineral has recently been accepted for coverage in the Emerging Sources Citation Index, which is the new edition of the Web of Science that was launched in November 2015. This means that any articles published in the journal will be indexed in the Web of Science at the time of publication.
Editorial Committee

Teresita Bellido, PhD
Chair of the Department of Physiology and Biophysics in the University of Arkansas for Medical Sciences (UAMS). Department of Medicine, Division of Endocrinology and Metabolism, Department of Orthopaedics, College of Medicine, University of Arkansas for Medical Sciences (UAMS). Research Career Investigator at the Central Arkansas Veterans Healthcare System-John L. McClellan Memorial Hospital. Little Rock. Arkansas (United States)
e-mail: tbellido@iupui.edu

Ernesto Canalis, PhD
Director, Center for Skeletal Research. Professor of Orthopedic Surgery and Medicine UConn Health. Farmington, CT (United States)
e-mail: canalis@uchc.edu

Patricia Clark Peralta, MD, PhD
Head of the Clinical Epidemiology Unit. Hospital Infantil de México Federico Gómez-Faculty of Medicine UNAM. Mexico City (Mexico)
e-mail: patricia.clark@promedica.org

Oswaldo Daniel Messina, MD, PhD
Director of Rheumatology. Cosme Argerich Hospital. Buenos Aires (Argentina). Medical Director IRO. Center for Rheumatological and Osteological Research. Buenos Aires (Argentina). Associate Professor of Rheumatology and Director of the post graduate programme in Rheumatology. University of Buenos Aires (Argentina). Board member and member of the Committee of Scientific Advisors. International Osteoporosis Foundation (IOF)
e-mail: drosvaldodanielmessina@gmail.com

Lilian I Plotkin, PhD
Department of Anatomy and Cell Biology and Indiana Center for Musculoskeletal Health Indiana University School of Medicine. Indianapolis, Indiana (United States)
e-mail: lplotkin@iupui.edu

Manuel Naves Díaz, MD, PhD
Bone Metabolism Clinical Management Unit. Central University Hospital of Asturias (HUCA). Institute of Health Research of the Principality of Asturias (ISPA). REDINREN of ISCIII. Oviedo University. Oviedo (Spain)
e-mail: mnaves.huca@gmail.com

Manuel Díez Pérez, MD, PhD
Hospital del Mar Institute of Medical Investigation (IMIM) and Internal Medicine Department. Hospital del Mar. Autonomous University of Barcelona. CIBER on Frailty and Healthy Aging (CIBERFES). Instituto Carlos III. Barcelona (Spain)
e-mail: adiez@parcesalutmar.cat

Jose Antonio Riancho, MD, PhD
Department of Medicine and Psychiatry. University of Cantabria. Service of Internal Medicine. Marqués de Valdecilla University Hospital. Valdecilla Research Institute (IDIVAL). Santander (Spain)
e-mail: rianchoj@unican.es

Manuel Sosa Henríquez, MD, PhD
University of Las Palmas de Gran Canaria. Research Institute in Biomedical and Health Sci Research Group in Osteoporosis and mineral metabolism. Bone metabolic Unit. Hospital University Insular. Las Palmas de Gran Canaria (Spain)
e-mail: manuel.sosa@ulpgc.es

María Jesús Gómez de Tejada Romero, MD, PhD
Department of Medicine of the University of Sevilla. Sevilla (Spain). Research Group in Osteoporosis and mineral metabolism. Bone metabolic Unit. Hospital University Insular. Las Palmas de Gran Canaria (Spain)
e-mail: mjgtr@us.es

Arancha Rodríguez de Gortazar, MD, PhD (Co-director)
University San Pablo CEU. School of Medicine. Institute of Applied Molecular Medicine (IMMA). Madrid (Spain)
e-mail: argortazar@ceu.es

Marta Martín Millán, MD, PhD (Co-director)
Internal Medicine Service. Marqués de Valdecilla University Hospital. Department of Medicine and Psychiatry. University of Cantabria. Santander (España)
Correo electrónico: marta.martim@scsalud.es

Methodology, Data Study and Statistics: Pedro Saavedra Santana
University of Las Palmas de Gran Canaria. Department of Mathematics. Las Palmas de Gran Canaria (Spain)
e-mail: pedro.saavedra@ulpgc.es

Rev Osteoporos Metab Miner. 2021;13(4):104

Reviewers Volume 13 (2021)

Ardura Rodríguez, Juan Antonio
Bárbara Bataller, Enrique
Blázquez Cabrera, José Antonio
Bou, Rosa
Cárcel Rey, José Ramón
Calvo Catalá, Javier
Carbonell Abella, Cristina
Casado Burgos, Enrique
de la Piedra Gordo, Concepción
Díez Pérez, Adolfo
García Giralt, Natalia
Junquera, Luis Manuel
Marín Díaz, Fernando
Martínez Díaz-Guerra, Guillermo
Martínez Laguna, Daniel
Monegal, Ana
Moró Álvarez, María Jesús
Muñoz Torres, Manuel
Naves Díaz, Manuel
Neyro Bilbao, José Luis
Olmos Martínez, Jose Manuel
Pérez Castrillón, José Luis
Peris Bernal, Pilar
Plotkin, Lilian
Portal Núñez, Sergio
Riancho Moral, José Antonio
Riaño Galán, Isolina
Rodríguez García, Minerva
Torrijos Eslava, Antonio
Valdés y Llorca, Carmen
Valero Díaz de la Madrid, Carmen

The SEIOMM Board of Directors and the Directorate of the Journal thank you for your invaluable collaboration.
Sequential treatment: it has come a long way... with a long way to go

DOI: http://dx.doi.org/10.4321/S1889-836X2021000300001

González Macías J
Professor of Medicine
Emeritus Professor at the University of Cantabria

Innovations in therapeutic behavior in the face of a certain disease are generally designed to improve effectiveness. But sometimes they may have other reasons. For example, avoiding side effects, lowering the cost or making the form of administration of a drug more comfortable. Sequential therapy represents a therapeutic innovation in the field of osteoporosis.

The first form of sequential therapy used in osteoporosis was probably called ADFR (A = activate remodeling, D = depress resorption, F = free formation, and R = repeat) or “coherence therapy”, initially proposed by Frost around 1980. The theoretical approach on which this strategy was based was to synchronize the remodeling units, placing them in the spring phase, by administering an osteoclast-stimulating drug, to then inhibit them. Afterwards, a free time of 2-3 months was left, during which the osteoblasts, activated by the coupling set in motion with the initial stimulus of the osteoclasts, were supposed to develop the osteoforming effect. The ADFR regimen was a therapeutic innovation that was intended to improve the efficacy of osteoporosis treatment, but it was a failed attempt.

The next form of sequential treatment that was considered in osteoporosis did so much later, some 20-25 years later. And, unlike the ADFR guideline, it was not established as a consequence of a theoretical reasoning, but arose as a necessity when it was found that the suspension of the administration of teriparatide was followed by a loss of the effects achieved with it, unless that an antiresorptive drug was administered. It was therefore a regimen that we previously described as intended to improve therapeutic efficacy.

Sequential therapy can also be applied in the field of osteoporosis to avoid side effects. In fact, the knowledge that prolonged treatment with potent antiresorptives (bisphosphonates, denosumab) can lead to serious complications, such as atypical femoral fracture (AFF) and osteonecrosis of the jaws, has led to at least two forms of sequential treatment in the management of the disease. One of them, only applicable to relatively young women (50-60 years) with mild-moderate osteoporosis that does not involve a risk of hip fracture, consists of administering during the first 6-8 years (depending on the age of the patient) a SERM, so that bisphosphonates or denosumab can be introduced later, and the patient can delay her exposure to the risk of the aforementioned complications. The other affects those patients who are already under treatment with these drugs, and have been doing so for at least five years before. In them, the possibility of stopping the drug (specifically in the case of bisphosphonates) should be considered, since it is known that this reduces the risk of AFF rapidly. The risk-benefit ratio must first be assessed. If bisphosphonate is discontinued, the risk of FAF decreases, but that of osteoporotic fracture increases. When this is small, the risk can be assessed. Withdrawal of the drug then places the patient on what we call “therapeutic holidays”. After these, the drug should be reintroduced, to return, perhaps, in the future to a new holiday period (bisphosphonate-holiday-bisphosphonate-holiday cycles, etc., with which the patient could remain adequately treated for the rest of his life). If the risk of osteoporotic fracture is great, what should be done, instead of suspending the treatment, is to administer a drug that does not carry the risk of the complications referred to: specifically, teriparatide (which Nelson Watts, in some ASBMR webinars, has called very graphically ”sabbatical period”, establishing an analogy with drug holidays). Both the sequence bisphosphonates-drug holidays-bisphosphonates, and the sequence bisphosphonates-teriparatide-bisphosphonates, are two good examples of sequential treatments aimed at avoiding complications. Discussing the extent to which the concept of therapeutic vacation could be applied to denosumab and that of sabbatical to romosozumab requires comments beyond the scope of this editorial.

Another reason that may motivate a change in osteoporosis treatment is perception, when assessing patient evolution. Response is inadequate and a change should be made (it may be debatable whether by changing drug the concept of “sequential therapy” is appropriate –in other pathology fields it would not be considered this way--; however, for the purposes of our discussion here, we can accept it). In such a case, the reported attitude could consist of one of these three possibilities: a) changing the drug considered insufficiently effective for another of the same, more potent type; b) change from an oral drug to an injectable one; c) change from an antiresorptive to an osteoformer. Today we might add, for certain occasions, a fourth possibility: the combination of two drugs, generally an osteoformer and an antiresorptive. Imagine, for example, a therapeutic failure of denosumab in a situation where, due to lack of availability or due to contraindication, romosozumab cannot be used since the administration of teriparatide after denosumab is not recommended. It could be switched to an association of teriparatide with zoledronic acid or even with denosumab itself. The combination, therefore, can constitute one more link in the therapeutic chain of sequential treatment.

The possible sequential guidelines for the treatment of osteoporosis are numerous. Fortunately, almost all of them have been studied and, consequently, we have a lot of information about them. But precisely their high number and the occasional existence of discrepancies in their results, require, in order to facilitate their knowledge, to carry out a necessarily laborious task of systematization and analysis. And this is exactly the task carried out by Drs. Casado and Neyro in the article published in this issue of the journal, facilitating our work in such a complex field.
The therapeutic sequences considered in this article constitute a sound basis on which to decide which specific treatment guidelines are appropriate. In some cases, the information we already have will suffice. But at other times, new studies will be needed to supplement the ones that have existed so far. The latter will occur, for example, when the current data come from studies whose outcome variables are not fractures, but others of a surrogate nature (in general, bone mineral density [BMD]). Or when it is necessary to include aspects not previously considered in the regimen in question, such as economics or those related to the convenience of drug administration.

There are multiple examples. The administration of denosumab after a bisphosphonate increases BMD more, but we lack data regarding the effect that this has on reducing fractures (this idea of reaching a certain BMD value—more specifically the T-index—responds to a concept that is very attractive—that of the "treat-to-target"—, which may possibly play an interesting role in the future, but which is currently not mature enough). In this regard, some authors7,8 have recently insisted on the similarity of the efficacy of zoledronate and denosumab in reducing the risk of fractures despite the greater effect of the latter on BMD. Osteoformers have been shown to be more effective than oral antiresorptives, but we do not know what would happen if they were compared with denosumab or zoledronate. Starting a treatment with an osteoformer to continue with an antiresorptive may be more effective than starting with the antiresorptive directly when the risk of fracture is very high. It has not been proven, however, that the same occurs when the risk is not so high. Incidentally, it is striking that authors who defend that this guideline is used in a practically generalized way explicitly indicate in their published findings that this proposal does not take into account economic aspects and the convenient use of the osteoformer9,10. Administering cycles of a bone-forming drug separated by that of an antiresorptive has also been considered a particularly effective osteoporosis treatment. The administration of two osteoformers in succession, one after the other, has even been suggested. Again, they are examples of suggestive theoretical approaches pending evaluation in practice both from the point of view of their efficacy and their viability (cost or acceptance by the patient).

Thus, sequential treatment, with its various modalities, represents a clear advance in the management of osteoporosis. The possibilities are numerous, but there are still aspects to be clarified. Experience with the ADFR regimen teaches us to be prudent in accepting therapeutic innovations. Reviews such as the one published by Drs. Casado and Neyro help us to proceed in a field that is becoming increasingly complex. We need to know how to distinguish what is already proven from what is not beyond mere speculation.

Bibliography

Sequential treatment in osteoporosis. New trends

DOI: http://dx.doi.org/10.4321/S1889-836X2021000300002

Casado E1,2, Neyro JL3,4
1 Rheumatology Service. University Hospital Parc Taulí (UAB). Sabadell (Spain)
2 Parc Taulí Research Institute (I3PT) (Spain)
3 Obstetrics and Gynecology Service. Cruces University Hospital (Spain)
4 University of the Basque Country. Baracaldo (Spain)

INTRODUCTION

Osteoporosis is a chronic systemic disease characterized by a deterioration in bone density and/or quality, which predisposes to a greater risk of fracture1.

All treatments for osteoporosis have shown greater or lesser efficacy in reducing the risk of fracture, especially in postmenopausal women2. This beneficial effect occurs from the modification of the bone remodeling process with the consequent increase in bone mineral density (BMD) and/or a modification of the bone’s microarchitecture, although this requires a prolonged treatment over years in most cases.

Although treatment with antiresorptives, menopausal hormone therapy [THM], selective estrogen receptor modulators [SERM], bisphosphonates [BP] and denosumab [DMAB]) can be maintained for at least 5-10 years, the balance between risk and benefit should always be taken into account, since in prolonged treatments with the highest antiresorptive potency drugs (BP and DMAB) an increased risk of some very infrequent complications such as osteonecrosis of the maxilla or atypical femur fracture has been described3,4.

In the case of bone-forming drugs (teriparatide [TPTD] and abaloparatide [ABL]) or dual-effect drugs (romosozumab [ROMO]), the duration of treatment is limited to a shorter period of time. TPTD and ABL (the latter not authorized for marketing in Europe) are not recommended to be administered for more than 2 years5,6, and ROMO should not be administered beyond 12 months7.

In recent years, the term sequential treatment has been gaining importance in the management of patients with osteoporosis, that is, the sequential use of different treatments to achieve maximum efficacy with the least risk of complications8.

Correspondence: Enrique Casado Burgos (ecasado@tauli.cat)
ADVANTAGES OF A SEQUENTIAL TREATMENT

In managing patients with osteoporosis, a sequential treatment strategy over the years is often required. After using a treatment for a certain period of time, it can be beneficial to discontinue or replace it with a different one, as a sequence.

There are several reasons that justify sequential therapy in patients with osteoporosis:

1. Osteoporosis is a chronic disease that requires long-term treatment, probably for many years.
2. Some treatments for osteoporosis have a maximum recommended duration (for example, 2 years for TPTD and ABL or 1 year for ROMO).
3. Some treatments are associated with some infrequent complications, especially if they are used for more than a certain time (for example, atypical femur fractures are more frequent in patients treated with BP for more than 5 years).
4. With some of the osteoporosis treatments there is a loss in BMD gain if a different one is not administered after its discontinuation.
5. In some cases, greater efficacy is achieved when a sequence of 2 or more drugs is used than if a single drug is used in the same period of time.
6. Patients tend to get tired and lose adherence to treatments, when they are administered very chronically for years, without changes in the administration guidelines.
7. Sometimes there is an inadequate response to treatment, either due to a loss of BMD or the development of new fractures despite following the treatment correctly; or simply an insufficient response to reach a therapeutic objective (“treat-to-target” strategy).

In all these situations we should propose a change in the treatment for osteoporosis. Although in some cases a temporary interruption might be better, in most situations it would be more appropriate to substitute a different treatment.

It is thus very important that the clinician knows the advantages and disadvantages of the different sequences of treatments in the patient with osteoporosis.

MECHANISM OF ACTION OF DRUGS FOR OSTEOPOROSIS

For the proper management of the patient with osteopo‐rosis, knowing how to select the best available therapy in each clinical situation is crucial, as well as discontinuing or changing when the risk-benefit balance recommends. It is therefore essential to be very familiar with the mechanism of action, effectiveness and safety of each of the drugs.

Menopausal hormone therapy (MHT)

Treatment with estrogens, alone or in combination with progestogens (depending on whether the patient retains her uterus or not), acts through the activation of nuclear estrogen receptors (ERα and ERβ) distributed in different body tissues. ERs receptors predominate in bone, their stimulation on the one hand inhibits osteoclastogenesis from the inhibition of the ligand of the activating receptor for nuclear factor kappa B (RANKL) and the stimulation of osteoprotegerin (OPG)10, and, on the other hand, effects on bone formation have been described, through the stimulation of factors such as IGF-1 or the inhibition of sclerostin11. In bone remodeling, MHT has an antiresorptive effect, with the consequent increase in BMD and a decrease in the risk of vertebral, non-vertebral and hip fracture, especially when administered in the first 5-10 years after the menopause12.

However, given the much debated risk of breast cancer and cardiovascular complications in prolonged estrogen treatments only confirmed in treatments started beyond the age of 60, it is currently assumed that MHT is reserved for women with premature ovarian failure and for those under 60 years of age with overt climacteric symptoms, in which the benefits clearly outweigh the risks13.

Selective estrogen receptor modulators (SERMs)

SERMs are a group of drugs with agonist activity at bone estrogen receptors, inhibiting resorption, and antagonist at estrogen receptors in the breast and endometrium, which is why they can provide the beneficial effect of estrogens in patients with osteoporosis, minimizing the effects of adverse effects on other organs14. Raloxifene (RLX) and bazedoxifene are the SERMs indicated in women with postmenopausal osteoporosis, since they increase BMD and reduce the risk of vertebral fracture. The unproven efficacy in reducing the risk of non-vertebral or hip fracture and the increased risk of venous thromboembolism restrict its use to postmenopausal women under 70 years of age at risk of vertebral fracture and low risk of hip fracture and venous thrombosis15.

Bisphosphonates (BP)

BPs are compounds derived from inorganic pyrophosphate with a high affinity for bone hydroxyapatite, which, when taken up by endocytosis by the osteoclast, inhibit farnesyl pyrophosphate synthetase and lead to cell apoptosis, with the consequent inhibitory effect on bone resorption16.

Alendronate (ALN) and risedronate (RIS), taken by mouth, and zoledronic acid (ZOL) by intravenous route, are the BP most widely used and recommended by clinical guidelines, given the demonstrated efficacy both in increasing BMD and in reducing the risk of vertebral, non-vertebral and hip fracture15,17. Ibandronate (IBN) is another oral BP, which, although it offers the advantage of its monthly administration, has only shown a reduction in the risk of vertebral fracture18.

Some infrequent complications associated with prolonged treatment with BP have been described, such as osteonecrosis of the maxilla and atypical fracture of the femur, with incidences of 0.1-1/10,000 and 1-2/10,000 patient-years, respectively15.

Denosumab (DMAB)

DMAB is a completely human monoclonal antibody, administered subcutaneously with a potent antiresorptive activity, through the blockade of RANKL19. DMAB has been shown to continuously increase BMD, for at least 10 years, and reduce the risk of vertebral, non-vertebral, and hip fractures15,19. DMAB has demonstrated superiority to BP in terms of increases in BMD, and its prolonged treatment has also been associated with osteonecrosis of the maxilla and atypical femur fracture, although also with a very low incidence20.

Teriparatide (TPTD) and abaloparatide (ABL)

TPTD and ABL are synthetic parathormone analogues (PTH 1-34 and PTHrP 1-34 respectively) with bone-forming activity and approved for treating osteoporosis with high risk of fracture (the EMA has only approved TPTD). Both drugs bind to the PTH receptor (although with affinity to different conformational states) and inhibit sclerostin, thereby stimulating osteoblastogenesis,
and decreasing apoptosis of osteoblasts. Later, and to a lesser degree, they increase RANKL secretion and thereby bone resorption.

Both treatments produce an increase in bone mass and improve the microarchitecture of the skeleton, especially in the trabecular bone, increasing bone strength and reducing the risk of fracture.

Both drugs are indicated in the treatment of patients with osteoporosis at high risk of fracture and have shown superiority over BP [22], but should not be administered beyond 2 years according to the technical data sheet.

Romosozumab (ROMO)
ROMO is a humanized antibody for subcutaneous administration with a dual effect on bone remodeling, as it inhibits sclerostin and secondarily RANKL, producing a rapid, but transitory, increase in bone formation (osteoformer) associated with a more sustained decrease over time of bone formation. As a consequence, with this treatment there is a marked increase in BMD (greater than with TPTD) and a decrease in the risk of fracture [23,24].

Unlike what happens with TPTD or ABL, the increase in bone formation that occurs with ROMO is mainly due to a marked increase in bone shaping (bone formation after activation of the lining cells in quiescent areas, without a process of prior resorption).

The beneficial effects of ROMO are both on the trabecular bone and on the cortical bone.

However, in its development, doubts have appeared in relation to cardiovascular safety, which have not yet been resolved. In the ARCH study, comparing with ALN, a higher incidence of serious cardiovascular events was observed in women treated with ROMO [25].

ROMO has been approved by the EMA, although as of the writing of this article it is not yet marketed in Spain.

According to the technical data sheet, it can only be administered for 12 months and is contraindicated in patients with a history of myocardial infarction or stroke [7]. In addition, the cardiovascular risk of patients should be assessed, based on risk factors, before and during its administration.

Discontinuing osteoporosis treatments
THM discontinuation
Discontinuation of estrogen treatment involves increased remodeling in some patients, with a rapid decrease in BMD and progressive loss of anti-fracture efficacy, which can be prevented with the administration of BP [26].

SERM treatment discontinuation
Discontinuation of treatment with X-ray is accompanied by a loss of BMD in both the lumbar spine and the femur, although less than that produced with estrogen interruption and proportional to the physiological loss that occurs with age [27].

Discontinuation of BP treatment
BPs are the only drugs for the treatment of osteoporosis with a residual effect on the skeleton after its discontinuation, the duration of which will depend on the affinity for hydroxyapatite of each BP, ranging between 1-2 years for RIS and IBN and 2-3 years for ALN and ZOL [28].

After discontinuation of treatment with BP, there is no immediate increase in remodeling, but rather this increase will appear progressively over time, which implies a stability or slight loss of BMD, while this residual effect lasts [28,29].

This property of BP justifies the possibility of considering a temporary suspension of treatment or therapeutic vacations in patients with low risk of fracture [30].

Discontinuation of DMAB treatment
DMAB has a reversible RANKL inhibition effect, so that discontinuation of treatment produces a rapid and marked increase in bone remodeling, with elevation of formation and resorption markers, as early as 9 months after the last dose, reaching levels even higher than those prior to treatment, and which did not normalize until after 24 months [30].

This “rebound” effect on remodeling is accompanied by a rapid loss of BMD, which can reach the values prior to the start of treatment (figure 1), and, in some patients, an increased risk of vertebral fractures, particularly multiple ones [30]. The incidence of vertebral fractures in women with postmenopausal osteoporosis who discontinue DMAB has been estimated between 8.5-10.5% in the 12-18 months after discontinuation [31,32], although some of these fractures could be due not only to the effect “Rebound”, but rather the return to a high-risk situation due to previous vertebral fractures that patients had before starting treatment with DMAB.

A systematic review of the literature carried out by a European Calcified Tissue Society (ECTS) working group demonstrated that the risk factors for the presentation of multiple vertebral fractures in patients who discontinue DMAB are young age, having prevalent vertebral fractures, a duration of treatment greater than 2.5 years, a greater gain in hip BMD during treatment, and a greater decrease in hip BMD after discontinuation [24]. Some case series indicate that previous treatment with BP could mitigate the rebound effect of remodeling (lower increase in markers) that occurs after discontinuation with DMAB, although it is not clear whether this attenuation prevents loss of BMD and fractures [30].

The administration of another potent antiresorptive treatment such as BP in patients who discontinue DMAB appears to have partial efficacy on the rebound effect that occurs. Experts recommend that patients who have received ABDM for less than 2.5 years and are at low risk of fracture can be treated with an oral BP for a minimum of 1-2 years (depending on bone markers and BMD). However, patients who have received DMAB for a longer time, those still at high risk of fracture, or those who cannot tolerate oral BP should receive a dose of ZOL 6 months after the last dose of DMAB, which could be repeated at 3-6 months, depending on the levels of bone markers [31].

Experts conclude that the indication for DMAB should be carefully assessed, especially in young patients, and that in those who discontinue treatment, a BP should be administered 6 months after the last DMAB injection, while there are no more data from new clinical trials.

Based on the data from the systematic review by Tsourdi et al. [24], we present a practical decision algorithm in patients receiving treatment with DMAB (figure 2).

In case an invasive dental procedure is necessary during treatment with DMAB, experts recommend that it be performed after the 5th month from the last dose, and the next dose is administered as soon as the surgical wound has healed [31].

Discontinuation of treatment with TPTD and ABL
Discontinuation of TPTD (and probably ABL) is accompanied by a loss of BMD in the spine and femur in the subsequent 12 months, being more marked in postme-
nepausal women (7.1%) than in men (4.1%)\textsuperscript{35}. The administration of an antiresorptive after discontinuation of TPTD maintains or even increases BMD\textsuperscript{36,37}.

**ROMO treatment discontinuation**

The effect of ROMO on bone remodeling is reversible, and its discontinuation is accompanied by a normalization of training and a "rebound" effect of resorption, which translates into a rapid loss of BMD in both the lumbar spine and the hip. (figure 3)\textsuperscript{38}. The previous administration of ALN seems to mitigate this "rebound" effect and attenuate the loss of BMD.

**Antiresorptive followed by another antiresorptive**

The administration of DMAB after having received ALN achieves greater suppression of remodeling and greater gain in BMD than the same treatment time with ALN alone\textsuperscript{39}. The ALN-DMAB sequence also appears more efficient than the ALN-ZOL sequence, at least in terms of DMO gain\textsuperscript{40}.

Therefore, in patients treated with oral BP who present a therapeutic failure or do not reach the goal of treatment, a reasonable option could be the transition to DMAB or ZOL, as long as its indication is clear and the administration of bone former.

On the other hand, and as mentioned above, in order to minimize the rebound effect that occurs on bone remodeling after discontinuation of DMAB, it seems advisable to administer a BP (oral or intravenous) at 6 months of the last injection of DMAB (figure 2).

**Antiresorptive followed by osteoformer**

Previous treatment with BP, especially with those with a higher affinity for hydroxyapatite (ALN and ZOL), seems to attenuate the BMD gain that occurs with TPTD\textsuperscript{41}, observing a decrease in the first 6 months of treatment\textsuperscript{42}, although anti-fracture efficacy seems to be maintained as demonstrated in a post-hoc analysis of the VERO study\textsuperscript{43}.

---

**Figure 1. Changes in bone mineral density of the lumbar spine (A), total hip (B) and 1/3 radius (C) during the 24 months of treatment with denosumab and during the 24 months after discontinuation. (Modified from Bone HG, et al.)**\textsuperscript{30}

**Figure 2. Decision algorithm in patients receiving denosumab treatment for osteoporosis. (Adapted from Tsourdi E, et al.)**\textsuperscript{34}

*\textsuperscript{*}: if zoledronate is not available, administer an oral bisphosphonate for 1-2 years.
However, the transition from RLX to TPTD does not seem to attenuate the osteoforming effect or the BMD gain of the latter\(^4\).

In the DATA-Switch study, the women who received DMAB for 2 years and switched to TPTD presented an increase in bone remodeling, with a marked decrease in BMD in the hip in the first year, but which recovered in the second year, returning to BMD values at the onset of TPTD (figure 4)\(^4\). Although there is no evidence whether this transient loss of BMD is accompanied by an increased risk of fracture, some experts suggest not discontinuing treatment with DMAB if TPTD (or ABL) is to be indicated, that is, combination therapy\(^4\).

In the STRUCTURE study, it was observed that, as occurs in the transition to TPTD, patients who received ALN and switched to ROMO had a lower increase in BMD than patients who received ROMO without prior antiresorptive treatment\(^4\).

Although anabolic treatment with TPTD or ROMO seems more effective in patients not previously treated with antiresorptive drugs, patients who, despite receiving antiresorptive treatment, present a high risk of fracture, probably obtain a greater benefit with the change to bone-forming treatment, except in the case of DMAB, which seems better to maintain a combination therapy with TPTD\(^4\).

The DMAB-ROMO sequence could be more favorable, since it has been reported that a second 12-month cycle of ROMO in patients who had received 12 months of DMAB after a first 2-year cycle of ROMO does increase spinal BMD lumbar (2.3%) and maintain hip BMD (figure 5)\(^4\). However, it must be taken into account that

---

**Figure 3.** Changes in bone mineral density in the lumbar spine (A) and total hip (C) during treatment with romosozumab and after discontinuation. The loss of BMD is less in patients who had previously received alendronate (B and D). (Modified from McClung MR, et al.)\(^3\)
these results have been extracted from a cohort of only 14 patients, and in whom DMAB had only been administered for one year.

**Osteoformer Followed by Antiresorptive**

Sequential TPTD-RLX treatment has been shown to be beneficial. RLX manages to maintain or even increase the BMD gain achieved with previous treatment with TPTD.

Equally beneficial is the TPTD-BP sequence. The BMD gain achieved with TPTD can be increased if, after its discontinuation, a BP is administered, also maintaining the anti-fracture efficacy.

But the TPTD-DMAB sequence is probably the one that provides the highest BMD gain (18% in the lumbar spine and 8% in the femoral neck after 2 years of treatment with TPTD followed by another 2 years of treatment with DMAB).

Depending on the clinical characteristics of the patient and the risk of fracture, we could select one antiresorptive or another after completing the two years of treatment with TPTD (figure 6).

A study with 68 postmenopausal women has recently been published comparing the efficacy of 3 repeated cycles of 6 months of TPTD followed by 6 months of DMAB (total 36 months), versus a standard treatment of 18 months of TPTD followed by 18 months of DMAB. After 3 years of treatment, the patients who received standard sequential therapy achieved greater gains in BMD in the lumbar spine (16% vs 12%; p=0.04), with no changes in hip and radius BMD. Cyclical therapy achieved better results in hip and radius BMD at 18 months, so according to the authors, repeated cyclical treatment of TPTD and DMAB could be potentially useful in patients at imminent risk of fracture, especially in patients at higher risk of non-vertebral fracture.

The ABL-BP sequence is also effective. In the extension of the ACTIVE study, the administration of ALN after ABL was shown to increase the BMD gain achieved with ABL and to maintain anti-fracture efficacy.

There are also data on the ROMO-antiresorptive sequence. In the ARCH study, it was observed how the BMD gain achieved with ROMO was maintained after switching to ALN. Regarding anti-fracture efficacy, the reduction in the risk of vertebral fracture was maintained and the reduction in the risk of non-vertebral fracture was increased.

In the FRAME study, the sequence 1 year of ROMO followed by 1 year of DMAB was equally beneficial in terms of gain in BMD and reduction of the risk of vertebral fracture. Although a lower incidence of clinical fractures and non-vertebral fractures was also observed with this sequential treatment than with a single year of ABMD, it must be said that the differences were not significant.

**Therapeutic Holidays**

In order to minimize the risk of long-term complications or improve patient adherence to treatment, a temporary interruption of antiresorptive treatment may be considered in the management of osteoporosis, but only with BP, both oral and intravenous, given its remaining effect on the skeleton.

The working group on the management of patients with osteoporosis on prolonged treatment with BP of the American Society for Research in Bone Metabolism (ASBMR) recommends considering therapeutic holidays after at least 5 years of treatment with oral BP or 3 years of ZOL, but only in patients under 70 years of age, without fractures before or during treatment and who do not have a hip BMD in the osteoporosis range or present risk factors for fracture or a high risk according to FRAX.

The duration of the therapeutic holiday will depend on the BP used, being greater in the case of BP with greater affinity for hydroxyapatite such as ALN (2 years) or ZOL (3 years), and lower (1-2 years) in the case of BP with lower skeletal affinity such as RIS or IBN.

It should be remembered that a temporary interruption cannot be considered with any other antiresorptive, and that doing so with DMAB could expose the patient to a situation of high risk of fracture, especially vertebral, especially among patients with a previous vertebral fracture, as already mentioned. It is precisely in these cases that one might ask the reasons for a suspension or interruption of treatment.

**Combination Therapy**

The combination of two antiresorptives has not been shown to be more effective than treatment with a single antiresorptive.

Nor does the combination of osteoformer with BP provide greater efficacy. The combined treatment of TPTD and ALN appears to be even less effective than TPTD alone. In any case, it could be somewhat more beneficial to add TPTD to treatment already started with BP or to add BP to treatment already started with TPTD, although more studies are needed to confirm this assumption.

Combined TPTD and ZOL therapy has been shown to achieve a faster increase in BMD in both the lumbar spine and the hip, although with no greater gain in BMD at 12 months than TPTD in monotherapy.

The most promising combination therapy is the simultaneous administration of TPTD and DMAB. In the DATA-Switch study, it was observed that the patients treated with the combination had greater increases in BMD in the spine and hip than the patients treated with each drug alone (figure 4).

According to the latest osteoporosis recommendations of the Spanish Society of Rheumatology, this combination could be justified in very selected cases of severe osteoporosis.

**Conclusions**

- Osteoporosis is a chronic disease that usually requires treatment for many years.
- For optimal management of the disease, the clinician must know very well the mechanism of action, efficacy and safety of each of the drugs, as well as the differences that exist according to the order of administration of the same.
- With the exception of BPs, which have a residual anti-fracture effect, discontinuation of treatment for osteoporosis is not favorable for the bone, being especially negative in the case of DMAB.
- For this reason, therapeutic holidays can only be considered in patients treated with BP with a low risk of fracture.
- The change from an antiresorptive to another antiresorptive with a different mechanism of action is an option that may be favorable in the management of some patients with osteoporosis.
Figure 4. DATA-Switch study. The denosumab-teriparatide sequence produces a marked decrease in bone mineral density in the hip in the first year of transition, which recovers in the second year (red). The teriparatide-denosumab sequence achieves a marked gain in BMD in the hip (blue), similar to the combination therapy followed by denosumab (green). (Adapted from Leder BZ, et al.)

Figure 5. Sequential denosumab-romosozumab treatment after a 2-year cycle of romosozumab succeeds in increasing bone mineral density in the lumbar spine and hip. (Adapted from Kendler DL, et al.)
Figure 6. Decision algorithm in patients who have completed two years of treatment with teriparatide for osteoporosis

- Although exchanging an antiresorptive for an osteoformer may be associated with a lower initial BMD gain (or even loss in the case of ABMD), this does not appear to have negative consequences on antifracture efficacy.

- Starting with bone-forming treatment (TPTD or ROMO) and then continuing with an antiresorptive is the best treatment sequence, so it could be the preferred option in patients with a very high risk of fracture.

Conflict of interests: Enrique Casado has received professional fees for conferences and consultancies from Eli Lilly, Amgen, UCB, Theramex, Gebro, Italfarmaco, Gedeon-Richter, STADA, Bayer, GP-Pharma and Rubió. José Luis Neyro has received professional fees for research studies, continuing education and consultancies from Abbott, Amgen, Exeltis, Faes, FarmaD, Gedeon-Richter, Italfarmaco, Procaps, Rafio, Rubió, STADA, and UCB.
Bibliography


**WNT16 rs2908004 missense variant acts as eQTL of FAM3C in human primary osteoblasts**

DOI: http://dx.doi.org/10.4321/S1889-836X2021000300003

**Martínez-Gil N, Patiño J, Ugartondo N, Grinberg D, Balcells S**  
Department of Genetics, Microbiology and Statistics. Biology Faculty. University of Barcelona, CIBERER, IBUR, IRSJD. Barcelona (Spain)

**Date of receipt: 13/05/2021 - Date of acceptance: 27/09/2021**

**Study awarded a FEIOMM research grant 2019.**

**Summary**

**Introduction:** WNT16 is a gene important in bone homeostasis, found in a complex region that also includes neighboring genes: ING3, FAM3C, and CPED1. In addition to its role in determining bone mineral density (BMD), there is evidence that the variants in WNT16 associated with BMD also affect the expression of these neighboring genes. Therefore, it is important to understand whether the variants in WNT16 associated with BMD affect the protein levels of WNT16 or if they do so by modifying the expression of these neighboring genes.

**Material and methods:** We have determined the expression levels of CPED1 and FAM3C in primary osteoblasts, and we have verified whether WNT16 variants behave as loci of quantitative expression traits (expression quantitative trait loci; eQTL) of these genes.

**Results:** The amino acid change variant rs2908004 in WNT16 acts as the eQTL of FAM3C in primary osteoblasts under the dominant model hypothesis.

**Discussion:** It is possible that the effect of this variant on BMD is due to the modification of the expression levels of FAM3C in addition to, or instead of, a direct effect of the mutant WNT16 protein resulting from the amino acid change.

**Key words:** Bone mineral density, WNT16, osteoporosis, transcription.

**INTRODUCTION**

WNT16 is a ligand of the Wnt pathway that has been extensively studied for its importance in regulating bone homeostasis. This has been confirmed with the phenotype of knock-out (KO) mice and conditional KO mice in osteoblasts (cKO), which show spontaneous fractures due to low cortical bone mineral density (BMD), low bone strength and high cortical porosity, keeping the volume of trabecular bone unchanged. On the contrary, Wnt16 overexpression in osteoblasts and osteocytes produces an increase in BMD and bone strength in both trabecular and cortical bone. Despite this, the precise mechanism by which WNT16 acts is not known and different studies indicate that the effect on canonical and non-canonical Wnt pathways could be tissue specific. In bone, WNT16 is expressed mainly by osteoblasts and carries out its function both by stimulating bone formation and by inhibiting its resorption indirectly through osteoprotegerin (OPG) or directly affecting the osteoclasts differentiation.

Several genome-wide association studies (GWAS) have shown an association between the locus containing WNT16 and various skeletal phenotypes, including BMD and risk of fractures. WNT16 is found in a complex region where several genes in the region show an important role in bone metabolism. The genes ING3 and CPED1 at 5 ' and FAM3C at 3' of WNT16 belong to this locus (figure 1). ING3 (Inhibitor Of Growth Family Member 3) is responsible for the regulation of chromatin, since it is part of the NuA4 histone acetyltransferase (HAT) complex that recognizes the trimethylated form of lysine 4 of histone H3. Other functions unrelated to chromatin regulation include apoptosis promotion, DNA repair, and modulation of cell mobility. ING3 is expressed in a multitude of tissues, especially in those with a higher proportion of cell growth, bone being one of those with the highest expression of ING3. The in vitro cellular model of ING3 KO mesenchymal cells shows involvement of osteoblastogenesis and stimulation of adipogenic differentiation.
Figure 1. Genes at the locus: ING3_1 (ENST00000315870.5), ING3_2 (ENST00000339121.5), CPED1_1 (ENST00000310396.5), CPED1_7 (ENST00000450913.2), WNT16_1 (ENST00000222462.2), WNT16_2 (ENST00000361301.2), and FAM3C (ENST00000359943.3) by GRCh37/hg19

No specific function is known for CPED1 (Cadherin Like And PC-Esterase Domain Containing 1) in humans or mice. In the latter, it is uniformly expressed in a variety of solid tissues, including bone, although it is not detected in the RAW264.7 cell line or in circulating leukocytes. Furthermore, CPED1 presents different isoforms due to alternative splicing and three active promoter regions during osteogenic differentiation, indicating a complex regulation during differentiation.

FAM3C (Family of sequence similarity 3c) is a cytokine-like growth factor expressed in a multitude of tissues, which plays a very important role in the epithelial-mesenchymal transition (EMT) and subsequent metastasis during cancer progression. Its relationship with bone metabolism has been confirmed with the KO mouse model, which presents alterations in the cortical and trabecular structure, with an increase in cortical BMD, which plays an important role in the epithelial-mesenchymal transition (EMT) and subsequent metastasis during cancer progression. Its relationship with bone metabolism has been confirmed with the KO mouse model, which presents alterations in the cortical and trabecular structure, with an increase in cortical BMD, which plays an important role in the epithelial-mesenchymal transition (EMT) and subsequent metastasis during cancer progression.

The relationship of the genes present at the ING3-CPED1-WNT16-FAM3C locus with bone metabolism and their repeated association with BMD raises the question of whether there is a single causative gene and, if so, which is it, or if instead, all genes are contributing to the phenotype. To this end, in the present work we have determined whether those WNT16 variants associated with BMD in a previous work by our group are found to modify the expression of neighboring genes CPED1 and FAM3C.

**MATERIAL AND METHODS**

**Cell culture**

Human primary osteoblasts (hOB) were used for the loci assays that determine quantitative differences in gene expression (expression quantitative trait loci; eQTL). The hOBs were obtained from trabecular bone fragments discarded from knee replacement operations performed on women with osteoarthritis and who did not have any other disorder that could affect bone quality. The study was approved by the Clinical Research Ethics Committee of the Parc de Salut MAR (registration numbers: 2010/3882/1 and 2013/5266/1) and was carried out in accordance with the Declaration of Helsinki, obtaining informed consent by written consent from all participants. The primary osteoblast culture protocol is described in Roca-Ayats et al. Briefly, bone samples were cut into small pieces and washed with phosphate-buffered saline (PBS; Gibco, Life Technologies). These pieces were cultured in 140-mm plates with DMEM supplemented with 10% FBS, 1% w/v, 0.4% fungizone (Gibco, Life Technologies) and 100 µg/ml of ascorbic acid (Sigma-Aldrich). When the cells reached confluence, they were divided into three 75-cm² flasks, one for DNA extraction, one for RNA extraction, and the third for freezing and storage. Cells at passage 2 or lower were used for all extractions.

**eQTL assay**

DNA was extracted from cultured hOBs using the Wizard® Genomic DNA Purification Kit (Promega), according to the manufacturer’s instructions. The concentration of the purified DNA and its quality was analyzed in a spectrophotometer (Nanodrop). The genotypes of the rs2908004, rs2707466, rs55710688 and(rs142005327 variants were evaluated by Sanger sequencing using BigDye® Terminator v3.1 (Applied Biosystems) in the Genomics facilities of the CCiT of the University of Barcelona. The primers (Invitrogen, Thermo Fisher) were designed using Primer3 Input 0.40 (table 1). The total RNA of the cultured hOBs was extracted using the High Pure RNA Isolation Kit (Roche), according to the manufacturer’s instructions and the quantification and quality of the RNA were checked using a NanoDrop spectrophotometer. RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher), according to the manufacturer’s specifications. RT-qPCR was carried out using UPL probes (Roche) on a LightCycler 480 Instrument II (Roche). HMBS gene expression was used as a normalization control and the relative quantification (fold change) was calculated using the second derivative method. The number and sequence of the probe used, as well as the primers used for the amplification of the CPED1, FAM3C and HMBS genes are shown in table 1.

**Statistic analysis**

For the statistical analysis of the eQTL, the WGassocia-tion function was used in RStudio. This function performs an association analysis between a given SNP and
a dependent variable (in this case the expression levels of CPED1 and FAM3C) in five different genetic inheritance models: codominant [homozygous for major allele vs. heterozygous vs. homozygous for minor allele], dominant [homozygous for major allele versus [heterozygous + homozygous for minor allele]], recessive [homozygous for minor allele versus [heterozygous + homozygous for major allele]], over-dominant [heterozygous versus [homozygous for allele major + homozygous for minor allele]] and log-additive [each allele modifies the risk by an additive amount].

RESULTS

Cis-eQTL analysis

The variants rs2908004, rs2707466, rs55710688 and rs142005327 of WNT16 have been described as cis-eQTLs, according to the GTEx database in different human tissues (table 2). Unfortunately, this database does not have information on any bone tissue. This is why, using our own database of human primary osteoblasts (n=45), we have tested whether these variants act as cis-eQTL of the neighboring genes of WNT16: CPED1 and FAM3C. Only the rs2908004 variant has shown a significant association with FAM3C expression levels under the dominant hypothesis (p=0.03, table 3, figure 2). In addition, the rs2908004 and rs2707466 variants show a trend towards significance with FAM3C expression levels under the codominance hypothesis (p=0.05491) and under the dominant hypothesis (p=0.06954), respectively (table 3, figure 2). The presence of the G allele (rs2908004) and the C allele (rs2707466) are associated with an increase in the expression of FAM3C (table 3, figure 2). On the contrary, we have not found a significant association or trend between the WNT16 variants analyzed and CPED1 expression levels (table 3, figure 2).

DISCUSSION

Over the past 20 years, many works have highlighted the importance of WNT16 in bone homeostasis. WNT16 is found at position 7q31.31 along with 3 other genes also related to bone metabolism. In a previous study by our group, we found that the variants rs142005327, rs55710588, rs2908004, and rs2707466 were associated with BMD in a cohort of postmenopausal women from the Barcelona area (BARCOS)32. To determine whether these variants are related to an effect on WNT16 or

Table 1. Primers used in the sequencing of four WNT16 SNPs and for the RT-qPCR of FAM3C, CPED1 and HMBS

<table>
<thead>
<tr>
<th>Primer name</th>
<th>F (5′→3′)</th>
<th>R (5′→3′)</th>
<th>Probe</th>
</tr>
</thead>
<tbody>
<tr>
<td>WNT16-rs55710688</td>
<td>GGTAGCTCCAGTAAGATTC</td>
<td>CAGATTACCGTGTCTTTGGT</td>
<td></td>
</tr>
<tr>
<td>WNT16-rs2908004-rs142005327</td>
<td>ACTTTCAACTGAGGCTGGGG</td>
<td>CTGAAACTGGGAGTCAAG</td>
<td></td>
</tr>
<tr>
<td>WNT16-rs2707466</td>
<td>TGGGACAAAACAAGAAAGGC</td>
<td>TGACACATGGGTGTGTAAC</td>
<td></td>
</tr>
<tr>
<td>FAM3C_qPCR</td>
<td>GGCAATGGAANACAGGAG</td>
<td>TGATGCGCTCAGAAACTCA</td>
<td>52</td>
</tr>
<tr>
<td>CPED1_qPCR</td>
<td>CCCAAGTCTGGCCCTTGGT</td>
<td>GAAGAATAGGCTTAACCA</td>
<td>6</td>
</tr>
<tr>
<td>HMBS_qPCR</td>
<td>TTGCCCTGGAGAAGATGAAG</td>
<td>CAGCATCAGAGGTTCCTC</td>
<td>79</td>
</tr>
</tbody>
</table>

F: primer forward; R: primer reverse.

Figure 2. Violin plots of the expression levels of FAM3C (top) and CPED1 (bottom) according to the three genotypes (homozygous for the majority allele, heterozygous, homozygous for the minority allele) of the 4 variants studied.

I: insertion; D: deletion.
to an effect on the expression of neighboring genes, we have verified whether they are acting as eQTL of FAM3C and CPED1. This work has allowed us to determine that the missense variant rs2908004 is acting as eQTL of the FAM3C gene under the hypothesis of a dominant model in human primary osteoblasts.

The missense variant rs2908004 (p.Gly72Arg/p.Gly82Arg) has been associated with different bone parameters by us and others. This amino acid change from glycine to arginine is considered tolerated and benign by the pathogenicity predictors SIFT and PolyPhen-2, so its effect on BMD could be due to its role as eQTL and not to a change in the resulting WNT16 protein.

It should be taken into account that to obtain a more robust statistical significance having a bank with a greater number of primary osteoblasts is required. Unfortunately obtaining these samples is difficult and we have only managed to enter 45 samples into our bank.

In addition, it would be interesting to determine the expression levels of other neighboring genes that may be influencing BMD such as ING3 or directly on the expression levels of WNT16, which have not been able to be quantified due to lack of RNA sample from primary osteoblasts.

**CONCLUSION**

Through this work we have determined that the variant rs2908004 of WNT16 regulates the expression levels of the neighboring gene FAM3C under the hypothesis of a dominant model. If this association is confirmed in a larger primary osteoblast bank, it would indicate that the association of this variant with BMD could be due, at least in part, to the variation of FAM3C expression.

### Table 2. Genes whose expression is modified by the variants rs2908004, rs2707466, rs55710688, rs142005327 in various human tissues (data extracted from the Genotype-Tissue Expression (GTEx) Portal)

<table>
<thead>
<tr>
<th>SNP</th>
<th>Gen</th>
<th>Tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2908004</td>
<td>CPED1</td>
<td>Artery - Tibial</td>
</tr>
<tr>
<td></td>
<td>CYCSP19</td>
<td>Testicle</td>
</tr>
<tr>
<td></td>
<td>FAM3C</td>
<td>Skin - NE and E; Brain - Frontal Cortex (BA9); Esophagus - Muscularis</td>
</tr>
<tr>
<td>rs142005327</td>
<td>CPED1</td>
<td>Artery - Tibial</td>
</tr>
<tr>
<td></td>
<td>FAM3C</td>
<td>Skin - NE and E; Muscle - skeletal; Heart - Left Ventricle; Chest - breast tissue; Heart - Atrial Appendix; Nerve - Tibial</td>
</tr>
<tr>
<td></td>
<td>WNT16</td>
<td>Adipose - Subcutaneous</td>
</tr>
<tr>
<td>rs2707466</td>
<td>CPED1</td>
<td>Artery - Tibial</td>
</tr>
<tr>
<td></td>
<td>CYCSP19</td>
<td>Testicle</td>
</tr>
<tr>
<td></td>
<td>FAM3C</td>
<td>Skin - NE and E; Brain - Frontal Cortex (BA9)</td>
</tr>
<tr>
<td>rs55710688</td>
<td>CPED1</td>
<td>Artery - Tibial</td>
</tr>
<tr>
<td></td>
<td>FAM3C</td>
<td>Skin - NE and E; Muscle - skeletal; Heart - Left Ventricle; Chest - breast tissue</td>
</tr>
<tr>
<td></td>
<td>WNT16</td>
<td>Adipose - Subcutaneous</td>
</tr>
</tbody>
</table>

NE: not exposed to the sun (suprapubic); E: exposed to the sun (lower leg).

### Table 3. Results of association of the 4 SNPs of WNT16 and the expression of CPED1 and FAM3C

<table>
<thead>
<tr>
<th>SNP</th>
<th>A may</th>
<th>A min</th>
<th>HWE</th>
<th>Codominant</th>
<th>Dominant</th>
<th>Codominant</th>
<th>Dominant</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs55710688</td>
<td>D</td>
<td>I</td>
<td>0.2597</td>
<td>0.90837</td>
<td>0.65906</td>
<td>0.44952</td>
<td>0.34621</td>
</tr>
<tr>
<td>rs2908004</td>
<td>G</td>
<td>A</td>
<td>0.2095</td>
<td>0.68815</td>
<td>0.38455</td>
<td>0.05491</td>
<td>0.03061</td>
</tr>
<tr>
<td>rs142005327</td>
<td>D</td>
<td>I</td>
<td>0.2325</td>
<td>0.84422</td>
<td>0.91336</td>
<td>0.49356</td>
<td>0.35142</td>
</tr>
<tr>
<td>rs2707466</td>
<td>C</td>
<td>T</td>
<td>0.2305</td>
<td>0.80454</td>
<td>0.50710</td>
<td>0.11531</td>
<td>0.06954</td>
</tr>
</tbody>
</table>

In bold, the significant associations (p<0.05) and in italics, those that show a trend. A may: majority allele; A min: minor allele; HWE: Hardy-Weinberg equilibrium.

**Conflict of interests:** The authors declare no conflict of interest.


Diet as a risk factor for hypovitaminosis D in the Spanish pediatric population

DOI: http://dx.doi.org/10.4321/S1889-836X20210003000004

Blarduni Cardón E1, Arrospide A2-4, Angulo Ugarte H5, Urrutia Etxebarria I10, Castaño González I6-8, Etxebarria I9, Mar J2-4, Grupo Goivide10
1 Osakidetza. Zumárraga Hospital. Pediatric Service. Zumárraga (Spain)
2 Osakidetza. OSI Debagoiena. Research Unit. Arrasate-Mondragón (Spain)
3 Biodonostia Institute. Chronic Diseases Economic Evaluation Group. Donostia-San Sebastián (Spain)
4 Kronikgune Institute. Chronic Diseases Economic Evaluation Group. Barakaldo (Spain)
5 Osakidetza. Bizkaia Family and Community Medicine Teaching Unit. Galdakao Hospital. Galdakao (Spain)
6 IIS Biocruces Bizkaia. Cruces University Hospital. Barakaldo (Spain)
7 CIBERDEM, CIBERER. Carlos IIII Health Institute. Madrid (Spain)
8 University of the Basque Country. Department of Pediatrics. Barakaldo (Spain)
9 Osakidetza. OSI Debagoiena. Traumatology Service. Arrasate-Mondragón (Spain)
10 Osakidetza. OSI Goierri-Alto Urola. Primary Care Centers. Zumárraga (Spain)

Summary
Objective: It is not clear whether diet in the Spanish general population is also a relevant determinant of hypovitaminosis D. The objective of the study was to analyze the impact of diet on the prevalence of hypovitaminosis D in healthy children.

Methods: Demographic, anthropometric, nutritional, analytical data and vitamin D (25 (OH) D) level were studied using an enzyme-immuno-analysis using an observational design in a sample of the pediatric population between 4 and 14 years old. The 24-hour reminder diet survey was evaluated with the DietSource 3.0 software. The probability of hypovitaminosis was analyzed using logistic regression.

Results: 280 healthy children with a mean age of 9.0 years were recruited. The prevalence of hypovitaminosis D (<20 ng/ml) was 18.15% and that of severe deficit (<10 ng/ml) 1.4%. Ethnicity, seasonality, skin phototype, and time of sun exposure were significantly associated with the presence of hypovitaminosis D. The distribution of nutrients did not show differences between the groups with and without hypovitaminosis except for Pyridoxine B6 and saturated fatty acids.

Conclusions: Diet plays a reduced role as a risk factor for hypovitaminosis D in healthy children and the relevant factors are those related to sun exposure. An adequate outdoor lifestyle, sun exposure free of sunscreens and dietary patterns that ensure a correct intake of vitamin D and calcium remain the ideal recommendations for the general population. Supplementation should be limited to risk groups.

Key words: Gipuzkoa, hypovitaminosis D, healthy population, risk factors, diet, sun exposure.

INTRODUCTION
Vitamin D is an essential micronutrient in bone and non-bone metabolism.1 The high prevalence of its deficit has been documented in multiple studies2-5. However, the definition of its reference values continues to be controversial and consequently doubts are raised about its diagnosis and treatment.6 Although rickets was eradicated in the mid 20th century with sun exposure and the enrichment of milk with vitamin D, in recent years there have been reports of rickets in different parts of the planet, the mainly affected black-skinned and exclusively breastfed babies7-9. While rickets is the most serious consequence of vitamin D deficiency, mere deficiency also has important health consequences6.

Studies that measure the level of vitamin D show great geographic variability due to the great regional differences in climate, sun exposure and diet. For this reason, there is a need to specifically investigate the role of the different determinants of hypovitaminosis D10 in each country. The diet meets only 10% of the human body’s vitamin D requirements, the remaining 90% being obtained through the photosynthesis process that occurs in the skin by the direct action of the sun’s rays11. Risk factors repeatedly identified in the literature as causes of hypovitaminosis (dark skin phototype, low sun exposure, lack of physical exercise, latitude >40° north, and winter and spring seasons) act by interfering in the second mechanism12-15. Other factors associated with hypovitaminosis such as maternal deficit, obesity or advanced age could be related to both mechanisms of obtaining vitamin D12-14.
In Spain there are numerous studies that measure hypovitaminosis D prevalence in children2-4,15,16. However, most focus on the risk factors related to sun exposure. Rodríguez-Sangrador et al. include dietary measurement of vitamin D intake15. Recently, the debate on the need to supplement with vitamin D was described as a puzzle in which the pieces begin to fit together and it was recommended to give vitamin D in adults to those who need it to maintain serum levels of 25 (OH) D above 20 ng/ml17,18. Clarifying whether schoolchildren with hypovitaminosis D have a deficit of intake in the diet would help to fit this piece to also supplement the child population. For this, it is necessary to jointly address both the factors associated with the exposure and synthesis and with the intake of vitamin D.

In this study, we analyze the impact of diet on the prevalence of hypovitaminosis D in healthy children in the Goierri-Alto Urola region to provide recommendations for the prevention of hypovitaminosis D in the school population.

**METHODS**

A cross-sectional observational design was used, with cluster sampling during a calendar year (September 1, 2012 to September 30, 2013). The study was carried out with the financing of a Research Grant from the Department of Health of the Basque Government (Project No. 2011111107) and was approved by the Ethics Committee of Gipuzkoa. The children participated after signing the informed consent form by their parents. The reference population was the one served by the Integrated Health Organization (OSI) Goierri-Alto Urola in Gipuzkoa and the sample was recruited among girls, boys and adolescents between 4 and 14 years old, who attended Primary Care Services, being their The main populations Beasain, with latitude 43.05 N, and Zumárraga, with latitude 43.11 N. During the study period they had an average solar irradiation of 10.4–11.8 MJ/m² (Euskalmet, Basque Meteorology Agency)19. It was estimated that a sample of 298 schoolchildren would be sufficient to achieve a precision of 4% in a universe of 891, with a 95% significance, losses of 10% and an estimated prevalence of 20%. The schoolchildren were recruited successively, coinciding with the months a day to also supplement the child population. For this, it is necessary to jointly address both the factors associated with the exposure and synthesis and with the intake of vitamin D.

An individual survey on feeding was conducted using a 24-hour recall survey (ER24hs). After conducting the analysis, the Primary Care pediatrician who recruited the student was in charge of reviewing and re-interviewing the parents on the standardized and self-completed questionnaire with the food eaten in the previous 24 hours. For the conversion of food into nutrients, the DietSource 3.0 program was used, which has a food composition table from Nestlé Healthcare Nutrition S.A. (A. Jiménez, P. Cervera and M. Bacardi). By managing the dishes and food eaten, this program breaks down the daily menu by estimating the amounts of immediate principles, nutrients and caloric distribution in each child’s diet. Although the method applied is less valid than records based on the weight of food consumed for three or more days, the literature that has compared them supports its use21,22.

Analytical determinations of phosphocalcic metabolism (calcium, phosphorus, magnesium, alkaline phosphatase, PTH, 25 (OH) D) were carried out in the OSI Goierri-Alto Urola laboratory. To measure the level of 25 (OH) D in serum, the Elecsys-Chemiluminescent Immunoanalysis kit was used. The cut-off point of 20 ng/ml was used to determine the levels of vitamin D that are considered deficient and 10 ng/ml for the cases with severe deficiency. The results were presented according to whether the values were within the normal reference ranges that were 10-65 pg/ml for PTH, 8.8-10.8 ng/dl for calcium, 3.0-6.5 mg/dl for phosphorus, 1.5-2.6 mg/dl for magnesium and for alkaline phosphatase <269 IU/L from 4 to 6 years and <300 IU/L from 7 to 12 years.

**RESULTS**

Univariate analysis was carried out using the Chi-square statistic or Fisher’s exact statistic for categorical variables and the Student’s t-test or the non-parametric Mann-Whitney U test was applied in the case of continuous variables as a function of its distribution. The level of significance used throughout the study was 5% and the analyzes were performed with the statistical software Staata version 13.0. Multivariate analyzes were carried out using logistic regression models in which the dependent variable was the probability of having hypovitaminosis and the independent variables were risk factors associated with exposure and intake of vitamin D. Variables to be included in the model were selected based on clinical interest and the level of significance in the univariate analysis. The goodness of fit of the models was evaluated using the well classified percentage, the area under the ROC curve and the Hosmer and Lemeshow test.

**Variables to be included in the model were selected based on clinical interest and the level of significance in the univariate analysis. The goodness of fit of the models was evaluated using the well classified percentage, the area under the ROC curve and the Hosmer and Lemeshow test.**

**RESULTS**

281 schoolchildren (140 boys and 141 girls) were recruited for the study. The global prevalence of hypovitaminosis D in this population, understood as serum 25 (OH) D values lower than 20 ng/ml, was 18.1%. Cases of severe deficiency (25 (OH) D <10ng/ml) represented 1.4%.

Table 1 shows the distribution of demographic data and other previously known risk factors in the sample, classifying schoolchildren according to a higher or lower vitamin D level (hypovitaminosis) of 20 ng/ml. Statistically significant associations were observed for season of the year, ethnicity, skin phototype, time of exposure to the sun, and age of the child. The mean vitamin D level in schoolchildren of Caucasian ethnicity was 29.83 ± 9.45 ng/ml, while among non-Caucasians it was 19.25 ± 9.71 ng/ml.
Table 1. Description of categorical variables of the sample according to vitamin D levels

<table>
<thead>
<tr>
<th></th>
<th>Vitamin D deficiency</th>
<th>Normal vitamin D</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>Total</td>
<td>51</td>
<td>18.1%</td>
</tr>
<tr>
<td>Season</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Winter</td>
<td>20</td>
<td>29.4%</td>
</tr>
<tr>
<td>Spring</td>
<td>17</td>
<td>31.5%</td>
</tr>
<tr>
<td>Summer</td>
<td>6</td>
<td>9.1%</td>
</tr>
<tr>
<td>Autumn</td>
<td>8</td>
<td>8.3%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Man</td>
<td>22</td>
<td>15.7%</td>
</tr>
<tr>
<td>Woman</td>
<td>29</td>
<td>20.6%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10 years</td>
<td>21</td>
<td>14.3%</td>
</tr>
<tr>
<td>&gt;=10 years</td>
<td>30</td>
<td>22.4%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>37</td>
<td>14.5%</td>
</tr>
<tr>
<td>Other</td>
<td>14</td>
<td>53.8%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepubertal</td>
<td>27</td>
<td>14.8%</td>
</tr>
<tr>
<td>Puberalanner</td>
<td>24</td>
<td>24.5%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6</td>
<td>17.1%</td>
</tr>
<tr>
<td>No</td>
<td>45</td>
<td>18.3%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sport</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than school</td>
<td>2</td>
<td>6.9%</td>
</tr>
<tr>
<td>School only</td>
<td>29</td>
<td>23.2%</td>
</tr>
<tr>
<td>School + two days</td>
<td>20</td>
<td>15.7%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin phototype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red/blond/brown</td>
<td>33</td>
<td>14.5%</td>
</tr>
<tr>
<td>Brown/black</td>
<td>18</td>
<td>34.0%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exhibition time</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 minutes</td>
<td>34</td>
<td>28.3%</td>
</tr>
<tr>
<td>&gt;30 minutes</td>
<td>17</td>
<td>10.6%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunscreen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>38</td>
<td>21.7%</td>
</tr>
<tr>
<td>Yes</td>
<td>13</td>
<td>12.3%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of filter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>41</td>
<td>20.6%</td>
</tr>
<tr>
<td>Yes</td>
<td>10</td>
<td>12.2%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>41</td>
<td>17.5%</td>
</tr>
<tr>
<td>Yes</td>
<td>10</td>
<td>21.3%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supplementation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>50</td>
<td>18.5%</td>
</tr>
<tr>
<td>Yes</td>
<td>1</td>
<td>10.0%</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Correspondingly, only 14.5% of Caucasians were in the group with vitamin D deficiency, compared to 53.8% of non-Caucasians, with the difference in the distribution by groups also significant (p < 0.001). Figure 1 shows the frequency of the percentages of vitamin D levels between children of Caucasian origin and those of non-Caucasian origin. The resulting distributions are clearly different. Laboratory tests were within normal ranges in all cases except PTH, which in 5 cases was above the cut-off point of 65 pg/ml.

Table 2 shows the comparison of the means for each of the micronutrients in the diet in the subsamples with levels greater or less than 20 ng/ml in vitamin D measured in serum. Statistically significant differences were observed in pyridoxine B6, saturated and monounsaturated fatty acids. The mean mg of vitamin D ingested was not statistically significant despite the fact that individuals with hypovitaminosis reported a 40% lower vitamin D intake.

The results of the logistic regression adjusted for season, sex, age (older or younger than 10 years), ethnicity and time of exposure to the sun show a statistically significant effect of pyridoxine B6 and saturated fatty acids (table 3). Increasing the intake of pyridoxine B6 by one milligram decreases 1.85 times the possibility of presenting vitamin D deficiency in our sample. Similarly, the intake of 1 gram more of saturated fatty acids the possibility decreases 1.04 times.

**DISCUSSION**

The main contribution of our work is that diet plays a reduced role as a risk factor for hypovitaminosis D in healthy children. On the contrary, and according to the literature, factors related to sun exposure are the determinants of the presence of insufficient levels of vitamin D. From a clinical point of view, it has two consequences. The first is that a correct diet should not be a reason not to assess the possible risk of hypovitaminosis in a schoolchild. Second, it highlights that known risk factors such as non-Caucasian ethnicity and seasons with less sun exposure continue to be factors that determine a vitamin D assessment in schoolchildren. The strengths of our study should be highlighted as the size of the sample, its representativeness of the healthy population, and the obtaining of 25 (OH) D determinations throughout a year. A limitation of our work is the type of nutritional survey used since the diet with a 24-hour ER at a single moment is a method with limited precision. In addition, ER24hs requires adequate recent memory, it is not recommended for children under 12 years of age and in these cases the contribution of the parents was recorded. However, the work of Rodríguez Sangrador et al. that conducts a survey on the frequency of food consumption in 2 months of the year and measures the level of vitamin D but does so in a population of only 47 adolescents. The difficulty of applying methods based on the weight of the food consumed over several days is the cause of the low number of published works. In the case of ER24hs we had trained interviewers, but we recognize the weakness of this type of survey in relation to recent memory and the low estimate of a person’s nutritional and energy contributions. Despite its limitations, the literature that has compared the methods for measuring nutrient intake indicates that the ER24hs provides valid, although less precise, information.
Table 2. Nutrient content of the 24-hour intake

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Vitamin D deficiency</th>
<th>Normal vitamin D</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 43</td>
<td>% 84.3%</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>87.41</td>
<td>25.01</td>
</tr>
<tr>
<td>Lipids (g)</td>
<td>86.86</td>
<td>25.50</td>
</tr>
<tr>
<td>Carbohydrates (g)</td>
<td>227.19</td>
<td>62.15</td>
</tr>
<tr>
<td>Energy (kcal)</td>
<td>2040.16</td>
<td>437.83</td>
</tr>
<tr>
<td>Proteins %</td>
<td>17.21</td>
<td>4.11</td>
</tr>
<tr>
<td>Lipids %</td>
<td>38.09</td>
<td>7.43</td>
</tr>
<tr>
<td>Carbohydrates %</td>
<td>44.63</td>
<td>8.00</td>
</tr>
<tr>
<td>Phosphorus (mg)</td>
<td>1294.27</td>
<td>347.95</td>
</tr>
<tr>
<td>Magnesium (mg)</td>
<td>235.31</td>
<td>77.57</td>
</tr>
<tr>
<td>Calcium (mg)</td>
<td>1002.79</td>
<td>338.96</td>
</tr>
<tr>
<td>Iron (mg)</td>
<td>13.04</td>
<td>4.31</td>
</tr>
<tr>
<td>Zinc (mg)</td>
<td>10.37</td>
<td>4.32</td>
</tr>
<tr>
<td>Sodium (mg)</td>
<td>1691.45</td>
<td>763.64</td>
</tr>
<tr>
<td>Potassium (mg)</td>
<td>2590.07</td>
<td>828.46</td>
</tr>
<tr>
<td>Iodine (mg)</td>
<td>44.90</td>
<td>30.04</td>
</tr>
<tr>
<td>Selenium (mg)</td>
<td>65.80</td>
<td>33.69</td>
</tr>
<tr>
<td>Copper (mg)</td>
<td>958.35</td>
<td>62.54</td>
</tr>
<tr>
<td>Fluorine (mg)</td>
<td>403.93</td>
<td>278.13</td>
</tr>
<tr>
<td>Chlorine (mg)</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Manganese (mg)</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Chromium (mg)</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Molybdenum (mg)</td>
<td>0.29</td>
<td>2.98</td>
</tr>
<tr>
<td>Vitamin C mg</td>
<td>104.56</td>
<td>92.29</td>
</tr>
<tr>
<td>Thiamine B1 mg</td>
<td>1.50</td>
<td>0.67</td>
</tr>
<tr>
<td>Riboflavin B2 mg</td>
<td>1.80</td>
<td>0.61</td>
</tr>
<tr>
<td>Nicotinic Ac mg</td>
<td>20.19</td>
<td>9.43</td>
</tr>
<tr>
<td>Pyridoxine B6 mg</td>
<td>1.92</td>
<td>0.97</td>
</tr>
<tr>
<td>Vitamin A µg</td>
<td>1568.10</td>
<td>1443.63</td>
</tr>
<tr>
<td>Vitamin D µg</td>
<td>3.92</td>
<td>9.49</td>
</tr>
<tr>
<td>Vitamin E mg</td>
<td>9.22</td>
<td>3.83</td>
</tr>
<tr>
<td>Free folic acid µg</td>
<td>84.34</td>
<td>50.44</td>
</tr>
<tr>
<td>Total folic acid µg</td>
<td>203.41</td>
<td>110.43</td>
</tr>
<tr>
<td>Cyanocobalam in B12 µg</td>
<td>4.99</td>
<td>8.83</td>
</tr>
<tr>
<td>Biotin µg</td>
<td>0.34</td>
<td>3.62</td>
</tr>
<tr>
<td>Saturated AG g</td>
<td>29.22</td>
<td>11.59</td>
</tr>
<tr>
<td>Monounsaturated FA g</td>
<td>41.40</td>
<td>13.83</td>
</tr>
<tr>
<td>Polyunsaturated FA g</td>
<td>8.52</td>
<td>4.87</td>
</tr>
<tr>
<td>EPA g</td>
<td>0.06</td>
<td>0.16</td>
</tr>
<tr>
<td>DHA g</td>
<td>0.09</td>
<td>0.29</td>
</tr>
<tr>
<td>Cholesterol mg</td>
<td>412.54</td>
<td>229.78</td>
</tr>
<tr>
<td>MCT g</td>
<td>0.01</td>
<td>0.13</td>
</tr>
<tr>
<td>Dietary fiber g</td>
<td>14.77</td>
<td>6.69</td>
</tr>
</tbody>
</table>

SD: standard deviation; g: grams; FA: fatty acids; EPA: icosapentaenoic acid; DHA: docosahexaenoic acid; MCT: medium chain triglycerides.
Table 3. Multivariate analysis of the probability of hypovitaminosis D, according to risk factors

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>AOR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summer-autumn season</td>
<td>0.17 (0.06, 0.42)</td>
</tr>
<tr>
<td>Sex female</td>
<td>1.45 (0.61, 3.44)</td>
</tr>
<tr>
<td>Age ≥ 10 years</td>
<td>1.21 (0.40, 3.62)</td>
</tr>
<tr>
<td>Non-Caucasoid ethnic group</td>
<td>17.67 (4.77, 65.46)</td>
</tr>
<tr>
<td>Exposure time &gt;30 min</td>
<td>0.45 (0.19, 1.06)</td>
</tr>
<tr>
<td>Pyridoxine B6 (mg)</td>
<td>0.54 (0.31, 0.95)</td>
</tr>
<tr>
<td>Saturated AG (gr)</td>
<td>0.96 (0.92, 1.00)</td>
</tr>
<tr>
<td>Vitamin D (μg)</td>
<td>1.02 (0.99, 1.06)</td>
</tr>
<tr>
<td>Fluorine (mg)</td>
<td>1.00 (1.00, 1.00)</td>
</tr>
<tr>
<td>Constant</td>
<td>0.38 (0.38)</td>
</tr>
</tbody>
</table>

Well ranked percentage 85.9%
Area under the ROC curve 0.87
Hosmer and Lemeshow test 0.382

AOR: adjusted Odds Ratio; AG: fatty acids; min: minutes.

Upon analyzing the different dietary micronutrients, statistically significant associations with hypovitaminosis D only appeared for pyridoxine B6 and saturated fatty acids in both the univariate and multivariate analyses, with no pathophysiological explanation for this finding. Among the micronutrients, the frequencies of magnesium, calcium and potassium intakes were deficient regarding the recommendations for each sex and age. Regarding vitamins, the same happened with folic acid and vitamins C, A, D and E. The 2005 Basque Country Nutritional Survey showed similar nutritional habits to ours24.

Our results indicate that hypovitaminosis D is associated with the same factors as in the literature25,26. The percentage with severe deficiency (<10 ng/ml of 25 (OH) D) was small (1.4%), as corresponds to a healthy population. Using 20 ng/ml as a cut-off point, the deficiency reached 18.15% prevalence. According to the American Institute of Medicine (USA), the level of 20 ng/ml covers the needs related to phosphocalcic metabolism of 97% of the population. However, with a cut-off point of ≤30 ng/ml, as established by other studies27, the level of hypovitaminosis D would reach 56.3%. Hypovitaminosis D was focused on risk groups such as the non-Caucasian population in which it was greater than 50%. In fact, a case of rickets in a non-Caucasian, Pakistani child was the trigger for this study. Other variables such as seasonality and weight were also relevant25,27. For this reason, the outdoor lifestyle, sun exposure free of sunscreen and dietary patterns that ensure a correct intake of vitamin D and calcium continue to be the recommendations to be followed by the general population. It is important to highlight that the population studied was healthy and that only 5 schoolchildren found elevated levels of PTH (>65 pg/ml). In no case were there clinical manifestations or alterations in calcium, phosphorus and magnesium levels were found. The five children underwent a subsequent clinical evaluation and analysis of phosphocalcic metabolism (alkaline phosphatase, calcium, phosphorus, magnesium, PTH and vitamin D), with normal examination and analysis. For this reason, it was considered that the alterations in PTH levels corresponded more to physiological variations of adaptation than to a response to a vitamin deficiency28.

Exposure to the sun for more than 30 minutes was statistically significant in the univariate analysis, but this relationship disappeared in the multivariate analysis with a significance level of 5% since the p was 0.67. This “anomaly” may be due to the sample size since, although the adjusted Odds Ratio was 0.45, its upper confidence interval exceeded one.

According to our results, population screening for vitamin D deficiency should not be performed and supplementing with it should be limited exclusively to risk groups28,27. The criteria for carrying out an analytical determination of 25 (OH) D and supplementing it, according to its results, have been described by expert committees28,30. However, these indications vary between different scientific societies. Thus, the American Pediatric Association (AAP)30 and the European Association of Pediatrics (EAP)31 reserve this indication for risk groups. A study by Saggese et al.28 in a global consensus in Italy proposes supplementing with vitamin D in children and adolescents with the following risk factors for vitamin D deficiency: non-Caucasian ethnicity with dark skin pigmentation, reduced exposure to sunlight (due to lifestyle factors, chronic illness or hospitalization, institutionalization, complex disability, covering with clothing for religious or cultural reasons) or constant use of sunscreen, international adoption, obesity, chronic diseases (kidney, liver, Malabsorption syndromes, chronic therapies (anticonvulsants-antiretrovirals-glucocorticoids-systemic antifungals). In all these situations it is necessary to monitor vitamin D status at least once a year.

The vitamin D needs are covered by 90% with sun exposure and the remaining 10% is achieved through the diet, so both factors should be specifically valued in the Primary Care programs of the child and adolescent population, both for its prevention, diagnosis and treatment. Currently the best option to increase the dietary intake of vitamin D is food fortification. In the European Union, countries are divided into 3 categories; those with a policy of mandatory fortification (Norway, United Kingdom), voluntary (Spain, Portugal) or that there is no fortification. In Spain, there are exceptions to some products used for a long time as the sole source of nutrients by some population groups (infant formulas for...
initiation, continuation and cereals – enteral and parenteral nutrition products for hospital use and low-energy diets for reduction of weight, whose fortification is mandatory for all member states of the European Union)\textsuperscript{31}.

In our country there is a tendency to fortify skimmed and semi-skimmed milk until reaching the vitamin D level of whole milk that is lost with the skimming process. In addition, there are other products on the market that are also fortified, such as cookies, yogurt, margarines, cheese, breakfast cereals, juices and beverages\textsuperscript{32}.

Children require less exposure to sunlight than adults to produce sufficient amounts of vitamin D, both because of their higher body surface area to volume ratio and because of the greater capacity of their metabolism to produce vitamin D\textsuperscript{33}. In relation to sun exposure, it is known that the effective dose of UV radiation to produce 1000 IU of vitamin D, which guarantees sufficient levels of it in the blood, is achieved with 25% of the minimum erythromatogenic dose (MED), which is equivalent to 10-15 minutes in 25% of the body surface (face, arms, hands), without sunscreen and in the central hours of the day, from 10 to 15 hours\textsuperscript{34}.

A varied, balanced diet adapted to the needs of the different stages of its evolution is key for adequate physical and psychological growth, to prevent diseases and to obtain an optimal state of health. Their vigilance makes the risk of a short- and long-term nutritional deficit generally unlikely. Despite this, it should not be a reason to rule out vitamin D deficiency risk.

Promoting adequate levels of vitamin D in schoolchildren and adolescents is important because nutritional rickets can develop throughout the pediatric age and because its deficiency negatively affects bone health\textsuperscript{35}. The comparison of the numerous studies that assess supplementing with vitamin D is very complex given the heterogeneity in the administration of vitamin D (interval, dose, duration) and the recruited population (sex, age, ethnicity, BMI, latitude of the country of residence, season of the year; baseline vitamin D status). In our region, an unfavorable latitude, there is little synthesis of vitamin D in late autumn, during the winter months and early spring. During this period, an adequate level of vitamin D is only maintained by endogenous stores accumulated during the previous summer or by exogenous supplements. The presence of hypovitaminosis D due to risk factors, the recommended doses are between 600 IU/day [reduced sun exposure] up to 1000 IU/day [multiple risk factors for vitamin D deficiency]. The way to supplement is with intermittent doses (weekly-monthly) from 5-6 years and especially during adolescence; continuous doses should be reserved for children with permanent risk factors for hypovitaminosis D\textsuperscript{28}.

This work recognizes the importance of vitamin D during the pediatric stage and the challenge posed by an individualized assessment according to age, seasonality, skin phototype, adequate outdoor lifestyle, the controlled and prudent use of sunscreens and patterns nutrients that ensure a correct intake of vitamin D and calcium. The study of vitamin D also implies an effort to reduce health inequalities since it focuses on a social group with a low socioeconomic level and associated with immigration. Thus, pediatric control of hypovitaminosis D in schoolchildren is at the same time an exercise in the implementation of public health strategies aimed at promoting children's health.

Acknowledgments: This project was funded by the Department of Health of the Basque Government (Project Number 2011111107).


Conflict of interests: The authors declare no conflict of interest.
Genetic relationship between pulmonary diseases of environmental or occupational origin and osteoporosis: a bioinformatic approach

DOI: http://dx.doi.org/10.4321/S1889-836X20210003000005

Andújar-Vera F1, García-Fontana C1,2,3, González-Salvatierra S1,2,4, Martínez-Heredia L1, Muñoz-Torres M1,2,3, García-Fontana B1,2,3
1 Bio-health Research Institute of Granada (IBS.GRANADA). Granada (Spain)
2 Endocrinology and Nutrition Unit. San Cecilio University Clinical Hospital. Granada (Spain)
3 CYBERFES. Carlos III Health Institute. Madrid (Spain)
4 Department of Medicine. University of Granada. Granada (Spain)

Summary
Objective: Identifying biomarkers that relate osteoporosis to occupational and environmental lung diseases.
Material and methods: Using integrated medical terminology databases, diseases related to lung diseases were obtained which, together with osteoporosis, were analyzed in DisGeNET to obtain the genes associated with each disease and form a protein-protein interaction network (PPI) through the Cytoscape StringApp. Applying different centrality algorithms using CythoHubba in Cytoscape, the 5 network proteins with the highest degree of centrality were selected.
Results: 9 diseases were included in the group of pulmonary diseases. 2,698 genes associated with lung diseases and osteoporosis were obtained. Genes associated with osteoporosis and with at least two of the included lung diseases resulted in a PPI network with 152 nodes and 1,378 axes. The proteins with the highest degree of network centrality were AKT1, ALB, IL6, TP53 and VEGFA.
Conclusions: There is a significant relationship between osteoporosis and the environmental lung diseases studied, through genes with dual involvement. We propose five important genes that link these diseases. This could provide a coherent basis for further research in this field.

Key words: osteoporosis, air quality, air pollution, lung disease, biomarkers, bioinformatics.

INTRODUCTION
Osteoporosis is currently defined as a systemic skeletal disease characterized by decreased bone mass and a structural alteration of the bone tissue that determines a decrease in bone resistance resulting in a significant increase in fragility and susceptibility to fractures1. The classic risk factors associated with the development of osteoporosis are age, a history of previous fracture or family history of osteoporosis, and prolonged estrogen deficiency2.

On the other hand, one of the most important risk factors for mortality at the population level is air pollution. The consequences derived from air pollution have a high economic and social impact. In 2015, the costs derived from pollution-related morbidity and mortality reached 21 billion dollars worldwide and an estimated number of premature deaths between 6 and 9 million people in 2060 due to outdoor air pollution 3. Air pollution has been shown to have a direct impact on health, causing various adverse effects4. The relationship between air pollution and environmental lung diseases has been reported in numerous studies4-6. Likewise, there is strong scientific evidence that relates poor air quality in different work environments with the development of different respiratory diseases7,8.

In the 1980s, the first studies were published that showed an association between air quality and bone quality, observing a significantly higher incidence of fractures in city dwellers compared to those residing in rural areas9-11. Since then, studies in this line have increased notably over the last few years, indicating that prolonged exposure to air pollution is linked to a decrease in bone quality12-14, and...
considered osteoporosis and fractures a modifiable risk factor. However, a recently published systematic review points to the existence of inconsistent associations between air pollution and osteoporosis risk, which could be explained by the heterogeneity in the characteristics of the subjects participating in the related studies published.

Despite the fact that scientific evidence suggests the relationship between lung diseases and osteoporosis, currently no special attention is paid to air quality as a potential bone health problem. Considering the increase in air pollution in recent years, delving into this topic to understand the cross paths between the harmful effects of air pollution and bone health is urgent.

In this context, the identification of robust genetic markers that are present both in environmental and occupational lung diseases related to pollution and air quality, as well as in diseases related to bone quality, will allow the development of preventive and therapeutic strategies focused on the population at highest risk. For this type of study, bioinformatics plays an important role, allowing us to identify, through the use of different tools and algorithms, molecules that can act as common biomarkers between different diseases. In this sense, our study aimed to build and analyze a protein-protein interaction network relating genes involved in different environmental and occupational lung diseases related to pollution and air quality, with genes associated with the development of osteoporosis, to identify biomarkers common in both diseases.

Material and methods
Data collection
First, a literature search was performed to obtain a selection of unified terms to determine pulmonary and occupational diseases. The unified medical terminology databases consulted were Unified Medical Language System (UMLS, https://www.nlm.nih.gov/research/umls/index.html) and Medical Subject Headings (MeSH, https://www.nlm.nih.gov/mesh/meshhome.html). Subsequently, each of the selected diseases was used to determine disease-associated genes (DGA) by using the platform DisGeNET (http://www.disgenet.org/home/), which integrates information on the relationship between genes and diseases from various sources of public data and literature on gene expression, biomarkers, association between variants and diseases, single nucleotide polymorphisms and associations of clinical phenotypes with the corresponding diseases.

Selection of seed genes
Once the genes associated with the different lung diseases (either environmental or occupational origin) and osteoporosis had been obtained, an initial filtering was carried out selecting those genes common to osteoporosis and with at least one of the lung diseases framed within this study. In a second phase, those genes associated with osteoporosis and with two lung diseases were selected to generate the protein interaction network (PPI).

Construction of PPI networks
To build the PPI network of genes associated with the diseases under study, the STRING application was used (1.6.0 version, released: 8 Sep 2020, http://apps.cytoscape.org/apps/stringapp) within the Cytoscape platform (versión 3.8.2, https://cytoscape.org/). The confidence cut-off point value was established at 0.7. Only those interactions with a value greater than or equal to 0.7 were considered significant. Proteins below this cut-off point and those unrelated to other proteins were discarded.

Study of centrality and identification of genes
Obtaining the central genes, that is, those important nodes with a high number of interactions towards other nodes, were selected using the CytoHubba complement in Cytoscape. Five calculation methods were used: Degree, Betweenness, Maximal Clique Centrality (MCC), Bottleneck and Closeness. The common genes derived from these six algorithms represent key candidate genes with important biological regulatory functions.

Results
Data collection
After reviewing the unified medical terms, the diseases included in table 1 were selected. These were used to compare the genes associated with each of them with osteoporosis. Diseases in which genes associated with the disease had not been identified were not included.

Selection of seed genes
After applying the criteria established for the inclusion of genes in the PPI network, 157 genes associated with osteoporosis and at least two lung diseases were obtained. The complete list can be viewed in the supplementary material.

Construction of PPI networks
The generated PPI network included 152 proteins (nodes) and 1,378 relationships (axes). Of this set, 12 proteins were discarded because they were not linked to other proteins (figure 1).

Table 1. Unified terms for diseases of this study and unique identification code

<table>
<thead>
<tr>
<th>SLMU CUI</th>
<th>Unified Term/Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>C0003165</td>
<td>Anthracosis</td>
</tr>
<tr>
<td>C0003849</td>
<td>Asbestosis</td>
</tr>
<tr>
<td>C0006542</td>
<td>Byssinosis</td>
</tr>
<tr>
<td>C0024117</td>
<td>Chronic obstructive airway disease</td>
</tr>
<tr>
<td>C0025500</td>
<td>Mesothelioma</td>
</tr>
<tr>
<td>C0029456</td>
<td>Osteoporosis</td>
</tr>
<tr>
<td>C0037116</td>
<td>Silicosis</td>
</tr>
<tr>
<td>C0026062</td>
<td>Interstitial lung disease</td>
</tr>
<tr>
<td>C0264423</td>
<td>Occupational asthma</td>
</tr>
<tr>
<td>C0340992</td>
<td>Summer-type hypersensitivity pneumonitis</td>
</tr>
</tbody>
</table>

*SLMU: unified medical language system; CUI: unique identification code.
Study of centrality and identification of genes

10 central genes were determined by means of the Cytoscape application from the centrality methods detailed in table 2. Next, the 5 genes that appeared most frequently in the different centrality algorithms were selected (table 3), which shared their presence in all the algorithms used, evidencing their importance within the constructed interaction network.

DISCUSSION

Any annual report on air quality reveals unflattering conclusions. The World Health Organization constantly warns about non-compliance with recommended standards for achieving healthy air quality. Poor air quality has a great health impact, causing 4.2 million premature deaths a year worldwide, mainly associated with exposure to small particles with a diameter less than or equal to 2.5 microns.22

The main health effects of exposure to an environment with poor quality or polluted air are known and have been scientifically proven for many years. These include lung cancer, respiratory and cardiovascular diseases, stroke, etc. However, there are other less known effects or with little scientific evidence associated with the lack of studies in this area.

Due to the aging of the population, osteoporosis is considered one of the most prevalent diseases in the population worldwide. Currently, the association between poor air quality and osteoporosis is not well defined in the scientific literature, but it is beginning to be of great importance due to the health impact of the high percentage of the population with osteoporotic problems or low bone quality.

The results of this study show a set of genes associated with the presence of both lung diseases (derived from environmental contamination or associated with certain occupational activities) and osteoporosis. Pulmonary diseases are mainly caused by repeated exposure over time to chemical irritants, allergens or toxins, which can cause lasting effects on the individual.

The bibliographic search of pulmonary diseases of environmental or occupational origin, offered a set of diseases that, without being a priori related to osteoporosis, could share one or more genes linked to osteoporotic processes. Thus, we find anthracosis, a lung condition produced by exposure and inhalation of dust with a high concentration of carbon; asbestosis, in which asbestos is the main inhaled particle; byssinosis, produced by inhaling cotton dust among other particles of plant origin; chronic obstructive pulmonary disease (COPD), a consequence of long-term exposure to irritants such as polluted air, chemical fumes or dust, among others; mesothelioma, a specific form of lung mesothelial cancer that is usually related primarily to occupational exposure to asbestos; silicosis, caused by inhaling dust with silica particles; interstitial lung diseases, which encompass a group of lung diseases most of which are caused by progressive scarring of the lung tissue due to prolonged exposure to dangerous substances (such as certain organic substances, wood, metals, infectious agents such as viruses, drugs, etc.); occupational asthma, produced by inflammation of the pulmonary airways caused by inhalation of substances produced in the workplace such as wood dust, fungi, and/or chemical substances, among others, and hypersensitivity pneumonitis, caused by exposure to a large number of organic particles such as fungi or bacteria, causing a significant inflammatory response.

This set of diseases derived from poor air quality has been related to osteoporosis, reflecting a high genetic relationship between the two types of diseases. The results of the present study are consistent with previous studies on the association of respiratory diseases with osteoporosis12-14. In addition, especially relevant genes have been obtained that could be considered as potential common markers between pulmonary and osteoporotic diseases.

Figure 1. Protein-protein interaction network of genes associated with the lung diseases of this study and linked to osteoporosis

Table 2. Ranking of genes of the biological network according to the centrality algorithm used

<table>
<thead>
<tr>
<th>Degree</th>
<th>Betweenness</th>
<th>*MCC</th>
<th>Bottleneck</th>
<th>Closeness</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF</td>
<td>TNF</td>
<td>TNF</td>
<td>VEGFA</td>
<td>TNF</td>
</tr>
<tr>
<td>VEGFA</td>
<td>SRC</td>
<td>VEGFA</td>
<td>AKT1</td>
<td>VEGFA</td>
</tr>
<tr>
<td>AKT1</td>
<td>VEGFA</td>
<td>AKT1</td>
<td>HGF</td>
<td>AKT1</td>
</tr>
<tr>
<td>MAPK3</td>
<td>AKT1</td>
<td>MAPK3</td>
<td>SPP1</td>
<td>MAPK3</td>
</tr>
<tr>
<td>IL6</td>
<td>MAPK3</td>
<td>IL6</td>
<td>IL6</td>
<td>IL6</td>
</tr>
<tr>
<td>EGFR</td>
<td>IL6</td>
<td>MAPK3</td>
<td>TP53</td>
<td>MAPK8</td>
</tr>
<tr>
<td>TP53</td>
<td>EGFR</td>
<td>TP53</td>
<td>VCAM1</td>
<td>EGFR</td>
</tr>
<tr>
<td>CXCL8</td>
<td>TP53</td>
<td>CXCL8</td>
<td>CAT</td>
<td>TP53</td>
</tr>
<tr>
<td>ALB</td>
<td>ALB</td>
<td>CCL2</td>
<td>ALB</td>
<td>ALB</td>
</tr>
<tr>
<td>STAT3</td>
<td>MAPK1</td>
<td>ALB</td>
<td>MAPK1</td>
<td>STAT3</td>
</tr>
</tbody>
</table>

*MCC: maximal clique centrality.
Table 3. Ranking of Genes with more presence in the applied centrality algorithms

<table>
<thead>
<tr>
<th>Genes</th>
<th>Unified name</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKT1</td>
<td>AKT Serine/Threonine Kinase 1</td>
</tr>
<tr>
<td>ALB</td>
<td>Albumin</td>
</tr>
<tr>
<td>IL6</td>
<td>Interleukin 6</td>
</tr>
<tr>
<td>TP53</td>
<td>P53 tumor protein</td>
</tr>
<tr>
<td>VEGFA</td>
<td>Vascular endothelial growth factor A</td>
</tr>
</tbody>
</table>

In systems biology, discovery of major proteins and their corresponding molecular pathways in complex diseases is booming thanks to PPI network analysis and enrichment analysis. The systems biology approach to investigating disease-associated biology is revolutionizing the understanding of cellular pathways and gene networks that underlie the onset of diseases, thus facilitating the discovery and development of new drugs and therapies thanks to the identification of markers in disease progression.

In biomolecular networks, where genes and/or proteins are nodes and the molecular interactions are the edges that interconnect the nodes, the importance of a node can be measured by the effect produced in the changes in the function of the interaction network, after deleting that node. These essential nodes are called hubs. In this study, 5 hubs have been determined that could consistently disturb the interaction network and that could cause important effects on the body’s fitness. The hubs that have been selected and that relate pulmonary diseases of environmental or occupational origin with osteoporosis are AKT1, ALB, IL6, TP53 and VEGFA, table 4. However, future studies could suggest new hubs that present a lower score in the classification performed in this study.

The role that these hubs play in osteoporotic processes and lung diseases is well known and corroborates the importance of the genes selected in this work to relate the diseases under study.

In the case of the AKT1 gene, which encodes the protein AKT kinase, it is found in various types of cells, playing important roles in many signaling pathways; in the case of osteoporosis, AKT1 acts as a negative regulator of osteoblast differentiation and as a positive mediator of osteoclastogenesis. It is therefore considered a potential target as a therapeutic target to improve osteoblast differentiation and bone mass formation while limiting osteoclast development and bone resorption. This protein also has pulmonary involvement, participating in the appearance and progression of pulmonary fibrosis, by promoting the differentiation of myofibroblasts and the deposition of proteins in the extracellular space and on the other hand, through the regulation of TSP1. Due to this, AKT1 has been proposed as a biomarker of interstitial lung disease, so that the use of AKT1 inhibitors such as triciribine, is considered as a potential therapeutic strategy for the treatment of these diseases. These data corroborate its dual role in both conditions.

Furthermore, the ALB gene encoding albumin was identified. Low levels of this protein have been associated with an increased risk of fractures due to low bone mineral density (BMD), with a positive correlation between serum albumin and BMD. In relation to lung diseases, an association between albumin and interstitial lung disease has been shown, with significantly lower levels of albumin being observed in patients affected with interstitial lung disease.

Interleukin 6, encoded by the IL6 gene, is considered a key factor in postmenopausal osteoporosis due to its ability to activate osteoclasts and induce bone resorption. Furthermore, it has been identified as a promising target for osteoporotic treatment due to its fundamental role as an inhibitor of osteogenesis and as a predictor of bone loss. In relation to lung diseases, we can highlight studies that correlate the overexpression of IL6 with COPD, although there are others that point in the opposite direction. With regard to silicosis, there are several studies that show increased levels of this cytokine from early stages of the disease, being considered as a potential biomarker for the early diagnosis and treatment of patients with silicosis. Likewise, there are studies that relate the increase in IL6 levels with the development of anthracosis. In this sense, several studies show an association of certain IL6 polymorphisms with the development of anthracosis and/or silicosis as well as with associated genotoxic effects.

With regard to the tumor protein p53, encoded by the TP53 gene, there are several studies that relate it both to osteoporosis and to different lung diseases. In this context, several studies show that increased serum levels of p53 are associated with a decrease in bone mass, and the suppression of p53 partially reverses the decrease in BMD in vitro and in vivo. In the case of lung diseases, it plays a leading role in the development of COPD, with increased levels of this protein being observed in affected patients. Likewise, an association between p53 and mesothelioma has been observed. In this sense, it has been reported that approximately 15% of patients affected with mesothelioma present some type of mutation in the TP53 gene. In the same way, in approximately 25% of human mesotheliomas there are co-deletions of the TP53 genes together with PTEN and/or CDKN2A/p14ARF, associating the cooperative losses of these genes with the development of a significant proportion of these aggressive neoplasms. These findings may lead to the establishment of appropriate therapeutic strategies for the joint treatment of both types of diseases.

Lastly, the VEGFA gene encoding vascular endothelial growth factor A is known to play an important role in bone biology by participating in endochondral ossification. Furthermore, VEGFA is expressed at high levels in osteoblast precursors and can stimulate osteogenic differentiation in various types of cells. On the other hand, decreased levels of VEGFA are reportedly associated with osteoporosis through an intracellular mechanism possibly mediated by the regulation of the transcription factor RUNX2, considered as a therapeutic target of the disease. This gene has also shown relevant activity in lung diseases, being an autocrine growth factor in mesothelioma and a potent mitogen for mesothelial cells.
VEGFA is involved in angiogenesis and stimulates neo-vascularization of tumors. In malignant mesothelioma, elevated levels of VEGFA and its receptor have been detected by immunohistochemistry and have been correlated with microvessel density, increased tumor necrosis, and worse survival. In this sense, drugs aimed at blocking VEGFA, such as bevacizumab, have recently shown their efficacy in the treatment of mesothelioma.

Despite the amount of information on the role of these genes in certain pulmonary and osteoporotic diseases, there are few studies that relate both types of diseases, therefore, it is necessary to delve into these aspects in order to identify possible common therapeutic targets. The association between lung diseases (triggered by air pollution or poor air quality in work environments) and bone quality could open the door to the design of behavioral strategies aimed at modifying the lifestyle that implies an improvement in bone health. On the other hand, it is important to consider the population with some type of lung disease, as a population at risk of bone fragility. Therefore, the knowledge provided by this type of study reveals the importance of studying BMD in people with lung diseases to establish early therapeutic and preventive measures in order to reduce the risk of fractures in this vulnerable population.

### Table 4. Genes with a high score in centrality associated with the pulmonary pathologies used in this study

<table>
<thead>
<tr>
<th>Genes</th>
<th>Unified name</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKT1</td>
<td>COPD, Mesothelioma, Silicosis, PID</td>
</tr>
<tr>
<td>ALB</td>
<td>COPD, PID</td>
</tr>
<tr>
<td>IL6</td>
<td>COPD, Mesothelioma, Silicosis, PID, Anthracosis</td>
</tr>
<tr>
<td>TP53</td>
<td>COPD, Mesothelioma, Silicosis, PID</td>
</tr>
<tr>
<td>VEGFA</td>
<td>COPD, Mesothelioma, PID</td>
</tr>
</tbody>
</table>

*COPD: chronic obstructive pulmonary disease; PID: pulmonary interstitial disease.*

### Conflict of interests:
The authors declare no conflict of interest.


21. Obeløvæn, Laronov AV, Kaluzhnyaya EV, Serebyukova ES, Yakovleva S. Druzhinin VG, et al. Associations of polymorphisms in the cytokine genes IL1β (rs16944), IL1β (rs10807955), IL12b (rs3212227) and growth factor VIB (rs2019963) with lung fibrosis in coal miners in Russia and related genotoxic effects. Mutagenesis 2018; 33: 129-135.


Muscle strength as a predictor of bone fragility in patients with type 2 diabetes mellitus

DOI: http://dx.doi.org/10.4321/S1889-836X2021000300006

Hayón-Ponce M1, García-Fontana B1,2,3, Avilés-Pérez MD1,2, González-Salvatierrra S2,4, Moratalla-Aranda E2,5, Muñoz-Torres M1,2,3,6
1 Unit of Bone Metabolism, Endocrinology and Nutrition. San Cecilio Clinical University Hospital. Granada (Spain)
2 Biosanitary Research Institute of Granada (IBS.GRANADA) (Spain)
3 CIBERFES, Carlos III Health Institute. Madrid Spain)
4 Foundation for Biosanitary Research of Eastern Andalusia (FIBAO). Granada (Spain)
5 Nuclear Medicine. San Cecilio Clinical University Hospital. Granada (Spain)
6 Department of Medicine. University of Granada (Spain)

Summary

Introduction: Most studies have shown a decrease in muscle function and strength in patients with type 2 diabetes mellitus (DM2). However, the relationship between muscle function and bone health in patients with DM2 is not well defined.

Objective: The objective of this study was to analyze the relationship between muscle strength and bone fragility in patients with DM2.

Material and methods: This observational cross-sectional study included 60 patients with DM2 (60% men and 40% postmenopausal women) ranging in age from 49 to 85 years. Demographic, anthropometric, clinical and biochemical variables were studied. Bone mineral density (BMD) in the lumbar spine (LS), femoral neck and total hip was determined using DXA (Hologic QDR 4500), and TBS values (TBS iNsight Software, version 3.0.2.0, Medimaps, Merignac, France). Hand grip (kg/cm²) was measured with a Jamar® manual hydraulic dynamometer (5030j1; Jackson, MI). To assess the level of mobility and the risk of falls, the Time Up and Go test was carried out. Statistical analysis was performed using the SPSS program (SPSS, inc, v 25.0).

Results: The mean age of the patients was 66.3±8.3 years. The mean HbA1c was 7.7±1.1%, with inadequate glycemic control (HbA1c >7.5%) observed in 73.3% of the patients. 91.7% of women and 77.8% of the men had low muscle strength. 41.7% of women and 25% of men presented a high risk of falls. Subjects with low hand grip strength and those with high risk of falls had significantly lower TBS values than those with greater hand grip strength (0.99±0.17 vs 1.12±0.15; p=0.03) and low risk of falls (0.94±0.13 vs 1.04±0.19; p=0.02). Patients with normal and partially degraded TBS had greater hand grip strength than subjects with degraded TBS (p=0.031). Hand grip strength was positively associated with TBS (p=0.05) regardless of age, waist circumference, 25OH vitamin D levels, and BMD in LS. There were no significant differences in hand grip strength as a function of BMD values.

Conclusion: Our study shows that the reduction in muscle strength may be related to bone microarchitecture deterioration determined by TBS in patients with DM2.

Key words: type 2 diabetes mellitus, hand strength, bone fragility, Trabecular bone score, bone densitometry.

INTRODUCTION

Type 2 diabetes mellitus (DM2) and osteoporosis are highly prevalent diseases due to the aging of the population that are associated with an increased risk of fragility fractures that substantially increase the morbidity and mortality of the population. Recently, sarcopenia, defined as muscle weakness related to aging, has been recognized as a complication of DM2 that often increases these patients’ frailty.
Most studies have focused on evaluating the relationship between muscle mass and bone mineral density (BMD), while only a few have assessed the effect of sarcopenia on bone quality. However, around two thirds of patients with fractures do not present osteoporosis as defined by BMD values. Patients with DM2 have an increased risk of fracture despite having preserved or even increased BMD. These results suggested that BMD alone is insufficient to assess bone strength and estimate fracture risk.

Sarcopenia was first defined by Rosenberg IH in 1988 as an aging-related loss of muscle mass and function. The state prior to sarcopenia is “dynapenia”, defined by Clark BC and Manini TM as a decrease in muscle strength related to aging before the reduction of muscle mass, determined through the evaluation of the knee extension strength and hand grip strength. Our objective was to investigate the relationship between the components of dynapenia determined by hand strength, and bone fragility determined by BMD and bone microarchitecture measured by DXA and TBS in subjects with DM2.

**Material and methods**

**Study population**

A cross-sectional observational study was carried out in which 60 patients with DM2 (60% men and 40% postmenopausal women) between 49 and 85 years old, recruited consecutively from 2016 to 2018 in the reference area of the San Cecilio of Granada Clinical University Hospital. The exclusion criteria included the presence of other conditions that alter bone metabolism such as the diagnosis of non-osteoporotic metabolic bone disease, chronic diseases, such as rheumatoid arthritis, chronic liver and kidney diseases and active neoplastic diseases, as well as hormone replacement therapy and glucocorticoid or antiosteoporotic treatment.

The study was carried out with the approval of the Ethics Committee of the San Cecilio Clinical University Hospital in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki). Written informed consent was obtained from all study subjects.

**Clinical evaluation**

Height, weight, and waist circumference (WC) were measured in all patients. Body mass index (BMI) was calculated as weight (kg)/height (m)².

The percentage of total body fat was estimated using a linear anthropometric equation called relative fat mass (RFM) applying the following equation: 64 - (20 x height/ waist circumference) + (12 x sex); sex = 0 for men and 1 for women.

The manual hand grip force (kg/cm²) was measured with a Jamar® hydraulic manual dynamometer (5030); Jackson, MI three times for each hand with the patient seated and the arm resting on a table holding the dynamometer in a vertical position, using the average value of these measurements to represent the strength of the hand. Hand grip strength values <27 kg (men) and <16 kg (women) were defined as low muscle strength.

**Bone densitometry and TBS**

Bone densitometry and TBS (Trabecular bone score) is a method for assessing the microarchitecture of the trabecular bone using TBS iNsight software (Medimaps, Mérignac, France). It is a simple application technique that permits microstructural analysis of the trabecular bone on DXA scan images of the lumbar spine with a new technological approach on the variation of image texture. Studies carried out to date have shown that the determination of TBS can predict the risk of fracture independently and in addition to BMD both in the general population and in patients with DM2.

Sarcopenia was defined as low muscle mass and function. The state prior to sarcopenia is “dynapenia”, defined by Clark BC and Manini TM as a decrease in muscle strength related to aging before the reduction of muscle mass, determined through the evaluation of the knee extension strength and hand grip strength. Our objective was to investigate the relationship between the components of dynapenia determined by hand strength, and bone fragility determined by BMD and bone microarchitecture measured by DXA and TBS in subjects with DM2.

**Biochemical determinations**

Blood samples were collected from all patients in the morning after an 8 hour overnight fast. Serum levels of albumin, calcium, phosphorus, creatinine, alkaline phosphatase, insulin, fasting plasma glucose, albumin, and lipid profile (triglyceride and cholesterol levels) were measured by standard biochemical methods.

Glycated hemoglobin (HbA1c) was determined by high performance liquid chromatography (ADAMS A1c, HA-8160; Menarini, Florence, Italy) and was expressed as a percentage.

**Bone densitometry and TBS**

BMD (grams/cm²) in the lumbar spine (LS), femoral neck (FN) and total hip (TH) was determined using a Holologic QDR 4500 densitometer (Whatman, MA) with a coefficient of variation of 1.70%, 1.80% and 1.50% for LS, FN and TH, respectively. The diagnosis of osteoporosis was made based on World Health Organization criteria.

TBS was measured in LS using TBS iNsight software version 3.0.2.0 (Medimaps, Mérignac, France) with a coefficient of variation of 1.82%. The bone microarchitecture classification was based on the following TBS ranges: TBS greater than or equal to 1.31 corresponded to normal microarchitecture, TBS between 1.23 and 1.31 was defined as partially degraded microarchitecture and TBS equal to or less than 1.23 as degraded microarchitecture.

**Statistic analysis**

Continuous variables were expressed as mean ± standard deviation (SD), while categorical variables were expressed as absolute (n) and relative (%) frequencies. The normality of the variables was analyzed using the Kolmogorov-Smirnov test. The difference between continuous variables was determined by Student’s t test. The Chi-square test was used to compare the categorical variables. Pearson’s correlation coefficient was used to evaluate linear relationships. Values of p<0.05 were considered significant. Multiple linear regression analysis was used to test the association between TBS and variables that influence bone quality, adjusted for other possible confounding factors. P values <0.10 were considered significant.

Statistical analysis was performed using the SPSS statistical program (version 25.0; SPSS, Chicago, IL, USA).
RESULTS

Table 1 shows the characteristics of the study subjects according to sex. The consumption of tobacco and alcohol, as well as cardiovascular disease and the time of evolution of DM2 was greater in men than in women, while women presented higher levels of total cholesterol and LDL cholesterol. Men presented lower RFM values and higher hand grip strength and BMD values in LS and TBS than women.

91.7% of the women and 77.8% of the men had low muscle strength. The prevalence of flow muscle strength was analyzed by age group, quartiles of BMI and WC (figure 1). When the prevalence of dynapenia was evaluated by age group, we observed a progressive increase with age (figure 1a). The prevalence of low hand grip strength was higher in the first and fourth quartiles of BMI. The prevalence of low muscle strength by quartiles of WC is shown in figure 1c; the group of the fourth quartile was the one that showed the highest prevalence of low hand grip strength.

According to the results obtained in the TUG test, 25% of men and 41.7% of women had a high risk of falls. Patients with high risk of falls showed significantly lower hand grip strength values than those with low risk of falls (13.8 ± 7.4 vs 18.7 ± 8.1; p = 0.027).

81.7% of the patients with DM2 had a degraded micro-architecture (TBS ≤ 1.23), 13.3% had partially degraded micro-architecture (TBS between 1.23 and 1.31) and 5% had normal values of TBS (TBS ≥ 1.31). According to the BMD values in LS, 3.7% of the patients were classified in the range of sarcopenia (T-score ≤ -2.5); 37% in that of sarcopenia and 59.3% had a BMD in LS normal. Subjects with normal and partially degraded TBS presented greater hand grip strength than subjects with degraded TBS (p = 0.031). However, there were no significant differences in hand grip strength between subjects with osteopenia/osteoporosis compared to those with normal BMD.

Mean DM2 evolution was 14.9 ± 8.7 years with inadequate glycemic control in 73.3% of the patients. Patients with a high risk of falls had longer term DM2 evolution than those with a low risk of falls (18.1 ± 8.9 vs 13.1 ± 8.1; p = 0.037). Patients with adequate metabolic control (HbA1c < 7.5%) showed greater hand strength, although no significant differences were observed with respect to the group with worse metabolic control. No significant association was observed between insulin treatment (66.7%) and the risk of falls or the presence of fractures.

Simple correlation analysis showed a significant positive effect on the bone microarchitecture (TBS ≥ 1.31) and negatively affect TBS values while hand grip strength (B = 0.284, [0.000 – 0.013], p = 0.038) exerts a positive effect on the bone microarchitecture determined by TBS.

DISCUSSION

Loss of muscle mass and strength, called sarcopenia and dynapenia respectively, has recently been recognized as a complication associated with diabetes mellitus3. Mori, et al. observed that the prevalence rate of dynapenia was higher than sarcopenia in patients with DM212. The European Working Group on Sarcopenia in the Elderly (EWGSOP)15 and the Asian Working Group on Sarcopenia (AWGS)20 consider hand grip strength as a simple method that reliably predicts deterioration in muscular function. The prevalence of sarcopenia in DM2 varies between 5% and 50% in the different studies carried out to date21. In a recently published meta-analysis, it were patients with DM2 reportedly had lower muscle strength than non-diabetic patients, despite no difference in muscle mass22. In our study, the prevalence of low muscle strength was 83.3%.

When analyzing the prevalence of low hand grip strength, we observed a progressive decrease with increasing age. Not surprisingly, increasing age represents a risk factor for low muscle strength in DM2, as well as in the general population, due to age-related decline in muscle mass and strength. However, it would be interesting to know if the age factor could be more decisive for the development of dynapenia and sarcopenia in individuals with DM2 compared to non-diabetic patients.

In this regard, Tamura, et al. did not show differences in the risk of sarcopenia according to age categories between individuals with and without DM221. Similarly, Çe-liker, et al. and Trierweiler, et al. observed a higher prevalence of sarcopenia in individuals with DM2 compared to those without DM2, while no significant differences were observed in terms of age22,25.

In previous studies, too low or too high a BMI and a high percentage of body fat have been associated with higher mortality26. According to the results of the body composition analysis, the prevalence of low muscle strength was higher in the first and fourth quartiles of BMI. However, the evaluation of the relative fat mass showed a significant progressive decrease in the manual grip strength with the increase of the quartiles of RFM. This finding suggests that diabetic patients with a high....

Subjects with low hand grip strength had significantly lower TBS values than those with greater hand strength (0.99 ± 0.17 vs 1.12 ± 0.15; p = 0.03). Although there was no significant correlation between the TUG test and TBS, lower TBS values were also observed in subjects with high risk of falls versus those with low risk of falls (0.94 ± 0.13 vs 1.04 ± 0.19; p = 0.02) (figure 3). There were no significant differences in BMD values in both groups. As shown in figure 4a, mean values of hand grip strength showed a progressive decrease according to the TBS categories. Furthermore, the percentage of patients presenting degraded TBS (TBS < 1.23) showed a decreasing trend with increasing quartiles of hand grip strength (figure 4b).

To determine the variables that influence the TBS (dependent variable), a multiple linear regression analysis was performed adjusting for the effect of age, WC, manual grip strength, levels of 25 (OH) vitamin D and BMD in LS. Our results showed that WC (B = 0.491, [-0.013 – 0.004]), p = 0.001 negatively affect TBS values while hand grip strength (B = 0.284, [0.000 – 0.013]), p = 0.038 exerts a positive effect on the bone microarchitecture determined by TBS.
### Table 1. Demographic characteristics and clinical variables

<table>
<thead>
<tr>
<th></th>
<th>Total (n=60)</th>
<th>Man (n=36)</th>
<th>Woman (n=24)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.35±8.09</td>
<td>66.19±7.62</td>
<td>66.58±8.92</td>
<td>0.857</td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>83.89±13.06</td>
<td>86.37±10.68</td>
<td>80.18±15.50</td>
<td>0.072</td>
</tr>
<tr>
<td>Size (cm)</td>
<td>165.09±8.25</td>
<td>169.54±6.32</td>
<td>158.42±6.03</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.80±4.60</td>
<td>30.11±3.95</td>
<td>31.86±5.36</td>
<td>0.152</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>103.83±11.44</td>
<td>104.60±9.42</td>
<td>102.95±13.58</td>
<td>0.635</td>
</tr>
<tr>
<td>RFM (%)</td>
<td>69.28±6.06</td>
<td>63.67±0.03</td>
<td>75.69±0.04</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Smoker (%)</td>
<td>56.7</td>
<td>75.0</td>
<td>29.2</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Alcohol (%)</td>
<td>23.3</td>
<td>33.3</td>
<td>8.3</td>
<td>0.025*</td>
</tr>
<tr>
<td>Sedentary lifestyle (%)</td>
<td>11.8</td>
<td>13.9</td>
<td>4.5</td>
<td>0.163</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>83.3</td>
<td>86.1</td>
<td>79.2</td>
<td>0.480</td>
</tr>
<tr>
<td>Dyslipidemia (%)</td>
<td>88.3</td>
<td>88.9</td>
<td>87.5</td>
<td>0.870</td>
</tr>
<tr>
<td>Overweight/Obesity (%)</td>
<td>86.7</td>
<td>88.9</td>
<td>83.4</td>
<td>0.535</td>
</tr>
<tr>
<td>Cardiovascular disease (%)</td>
<td>45.0</td>
<td>63.9</td>
<td>16.7</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Microvascular complications (%)</td>
<td>33.3</td>
<td>41.7</td>
<td>20.8</td>
<td>0.094</td>
</tr>
<tr>
<td>Falls (%)</td>
<td>30.0</td>
<td>25.0</td>
<td>37.5</td>
<td>0.301</td>
</tr>
<tr>
<td>Fractures (%)</td>
<td>13.3</td>
<td>11.1</td>
<td>16.7</td>
<td>0.535</td>
</tr>
<tr>
<td>Basal glucose (mg/dl)</td>
<td>147.97±52.27</td>
<td>144.08±51.03</td>
<td>153.79±54.66</td>
<td>0.486</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.7±1.13</td>
<td>7.64±1.24</td>
<td>7.79±0.96</td>
<td>0.612</td>
</tr>
<tr>
<td>Time evolution of DM2 (years)</td>
<td>14.93±8.68</td>
<td>16.81±9.21</td>
<td>12.13±7.10</td>
<td>0.031*</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>162.65±44.06</td>
<td>150.33±39.06</td>
<td>181.13±45.44</td>
<td>0.007*</td>
</tr>
<tr>
<td>HDLc (mg/dl)</td>
<td>45.35±12.19</td>
<td>42.14±10.36</td>
<td>50.17±13.33</td>
<td>0.054</td>
</tr>
<tr>
<td>LDLc (mg/dl)</td>
<td>87.83±36.84</td>
<td>80.36±32.66</td>
<td>99.04±40.48</td>
<td>0.01*</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>155.02±74.55</td>
<td>146.61±71.84</td>
<td>167.63±78.26</td>
<td>0.289</td>
</tr>
<tr>
<td>Hand grip (Kg)</td>
<td>17.29±8.12</td>
<td>22.5±5.62</td>
<td>9.47±3.82</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>TUG (s)</td>
<td>11.74±4.35</td>
<td>10.39±2.75</td>
<td>13.70±5.45</td>
<td>0.01*</td>
</tr>
<tr>
<td>BMD_LS (gr/cm²)</td>
<td>1.07±0.22</td>
<td>1.12±0.23</td>
<td>0.99±0.16</td>
<td>0.032*</td>
</tr>
<tr>
<td>BMD_FN (gr/cm²)</td>
<td>0.82±0.15</td>
<td>0.84±0.14</td>
<td>0.78±0.17</td>
<td>0.157</td>
</tr>
<tr>
<td>BMD_TH (gr/cm²)</td>
<td>1.04±0.17</td>
<td>1.07±0.17</td>
<td>0.99±0.18</td>
<td>0.082</td>
</tr>
<tr>
<td>TBS</td>
<td>1.0±0.18</td>
<td>1.06±0.17</td>
<td>0.94±0.17</td>
<td>0.012*</td>
</tr>
</tbody>
</table>

RFM: relative fat mass; BMI: body mass index; WC: waist circumference; HbA1c: glycated hemoglobin; HOMA2‐IR: insulin resistance index; HDLc: high-density lipoprotein; LDLc: low-density lipoprotein; TUG: test Time Up and Go; TBS: Trabecular bone score; BMD: bone mineral density; LS: lumbar spine; FN: femoral neck; TH: total hip; SD: standard deviation. Continuous variables are expressed as mean ± SD. Categorical variables are expressed as percentages. P values were determined using Student’s test for continuous variables and the Chi-square test for categorical variables. * Significance level <0.05.
percentage of body fat and a low or too high BMI present an increased risk of developing dynapenia. Furthermore, our results showed an inverse association between WC and TBS, suggesting a predictive role for WC regardless of age, hand grip strength, 25(OH) vitamin D levels and BMD in LS. These results support the role of central fat mass in bone microarchitecture determined by TBS\(^{27,28}\). Therefore, the assessment of obesity in diabetic patients should not focus solely on BMI. Rather, it should be considered in combination with body fat mass.

Although the link between sarcopenia, risk of falls, and risk of fractures has been studied in the general population, there are few studies that have examined the clinical impact of sarcopenia and bone fragility in patients with DM2. Our study analyzed the relationship between hand strength and bone fragility measured by BMD determined by DXA and the bone microarchitecture estimated by TBS in patients with DM2.

There are inconsistent results regarding the relationship between hand grip strength and BMD. Aydin’s group concluded that hand grip strength was not a good predictor of BMD in men\(^{29}\) while Pereira’s group did observe a significant correlation between hand grip strength and BMD\(^{30}\). In our study, we did not observe an association between hand grip strength and BMD.

Most of the studies that have evaluated the relationship between sarcopenia and bone quality have used data derived from invasive techniques such as quantitative computed tomography (QCT), presenting a limitation in routine clinical practice due to its low availability\(^{24,32}\). TBS is a non-invasive technique for evaluating bone quality that can predict the risk of fracture independently and in addition to BMD in patients with DM2\(^{10}\). In our study, we observed a positive relationship between hand grip strength and TBS values. Subjects with lower hand grip strength had lower TBS values and a decreasing trend was observed in the prevalence of degraded TBS (TBS <1.23) with increasing hand grip strength quartiles. In agreement, our results showed a positive association between TBS and manual grip strength independent of the effect of age, WC, levels of 25 (OH) vitamin D and BMD in LS in the multivariate analysis. These findings suggest that the measurement of manual grip strength could be an easily implemented strategy to estimate the state of bone microarchitecture in clinical practice.

Our results concur with the study carried out by Hammel’s group, which showed that TBS was positively correlated with hand grip strength in women\(^{31}\) and with the STRAMBO study, which showed that bone size and not bone size BMD seemed to correlate mainly with muscle mass, while bone microarchitecture was mainly correlated with muscle strength\(^{32}\). Our results confirm previous data and suggest that muscle strength has a greater influence on bone quality than on BMD and may reflect a deterioration of bone microarchitecture more reliably than bone status measured by BMD. Therefore, low muscle strength could be a good predictor of bone fragility measured by TBS in patients with DM2.

Both sarcopenia and dynapenia increase the risk of falls in patients with DM2\(^{19}\). The TUG test assesses the level of mobility and the risk of falls and is an indicator of severe sarcopenia\(^{15}\). Lower TBS values and hand strength in patients with a higher risk of falls suggests that the higher risk of fragility fractures in these patients could be related to the coexistence of severe sarcopenia and deterioration of the microarchitecture trabecular bone despite increased BMD.

The etiology of the effect of DM2 on the musculoskeletal system is multifactorial and not entirely well known\(^{34}\). Previous studies suggest that a longer duration of diabetes and sustained hyperglycemia affect muscle weakness in patients with DM2\(^{25}\). In our study, patients with a high risk of falls had a greater evolution of DM2 than those with a low risk of falls. However, we did not observe significant differences in the time of evolution of
the disease between subjects with normal or decreased muscle strength. Some studies have reported a higher prevalence of sarcopenia associated with longer term diabetes. However, other studies have not found a relationship between the prevalence of sarcopenia and the time of DM2 evolution.

A recent study has shown that hyperglycemia itself reduces muscle mass through increased KLF15 in myocytes. On the other hand, Kalyani, et al. observed that HbA1c is associated with weakness in muscle strength independent of muscle mass. In agreement, our results showed that patients with adequate metabolic control (HbA1c <7.5%) presented greater muscle strength in the hand, although no significant differences were observed between both groups, probably due to the limited number of patients included in the study. However, previous studies have not found a relationship between metabolic control and muscle strength. Therefore the prevention of the development of dynapenia and sarcopenia cannot be exclusively focused on metabolic control, in older patients, especially in elderly patients. Other factors must be taken into account, such as the presence of micro and macrovascular complications, body composition, nutritional status, and life expectancy, which determine morbidity and mortality.

Our study has certain limitations. First, the cross-sectional design of the study allowed investigating the association between study variables, but not causality. Second, the sample size was relatively small; however, our participants are representative of patients with DM2 in daily clinical practice. Third, we did not assess muscle mass, which is a determinant of sarcopenia, although when the components of sarcopenia have been examined individually in other studies, only low muscle strength was associated with recurrent incidence of falls, independent of muscle mass or gait speed.

Despite these limitations, to our knowledge, the present study is the first to investigate...
Muscle strength as a predictor of bone fragility in patients with type 2 diabetes mellitus

Conflict of interests: The authors declare no conflict of interest.

Figure 4. a) Mean values of manual pressure force according to the TBS categories. b) Prevalence of degraded bone microarchitecture (TBS ≤1.23) according to quartiles of hand grip strength

Hand grip force (kg/cm²) was measured with a Jamar® hydraulic hand dynamometer. TBS: Trabecular bone score; PD: partially degraded. The classification of bone microarchitecture was based on the following TBS ranges: TBS ≥1.31 corresponded to normal microarchitecture, TBS between 1.23 and 1.31 was defined as partially degraded microarchitecture and TBS ≤1.23 as degraded microarchitecture. Q1, first quartile, <9.5 kg/cm²; Q2, second quartile, 9.5-19.7 kg/cm²; Q3, third quartile, 19.8-23.5 kg/cm²; Q4, fourth quartile >23.5 kg/cm².

In conclusion, our study suggests that patients with DM2 present a high prevalence of age-related decrease in muscle strength. The results of the body composition analysis highlight the importance of assessing fat mass rather than assessing BMI in diabetic patients at risk of sarcopenia. A low or too high BMI and a high percentage of body fat tend to increase the risk of developing dynapenia. The TBS in patients with DM2 is usually low despite an increased BMD. Muscle strength was significantly associated with a deterioration in bone microarchitecture. The decrease in manual grip strength and the TUG test can be an easily applied tool in routine clinical practice to identify patients with DM2 at risk of falls and osteoporotic fractures.


